

SURVEILLANCE OF RARE CANCERS IN EUROPE



GRANT AGREEMENT No. 2006113

**WORK PACKAGE No.5
DELIVERABLE No. 13**

**TECHNICAL REPORT WITH BASIC INDICATORS FOR RARE CANCERS
AND HEALTH CARE RELATED MACRO INDICATORS**

Prepared by :

Gemma Gatta, Jan Maarten van der Zwan, Sabine Siesling, Renée Otter, Andrea Tavilla, Sandra Mallone, Annalisa Trama, Michael Schaapveld, Laura Ciccolallo, Roberta De Angelis, Angelo Paolo Dei Tos, Paolo Casali, Lisa Licitra and Riccardo Capocaccia.

Revised version february 2010

Table of contents

Intoduction	3
Materials	3
Selection of CRs and population coverage	
Rare tumours selection	
CRs data quality analysis	
Methods	6
Burden indicators	
Results	8
Incidence	
Prevalence	
Mortality	
Relative survival	
Stratified Analysis	
Discussion	10
References	12
Tables	13

INTRODUCTION

Rare tumours are a challenge to clinical practice; diagnostics, staging and treatment experience are often limited even in major cancer centres to which rare tumours are usually referred. The burden of rare tumours in Europe is still unknown, and no generally accepted definition exist. There are large variation in survival over time and across Europe, with poorer outcome among older patients and in eastern European countries [1]. For many rare tumours, research is confined to case reports or small retrospective series, for which substantial selection bias occurs and total experience is commonly too limited for any firm conclusions to be made. Selection bias can be limited by use of population-based Cancer-Registries (CRs) data and by compilation of large international databases on rare tumours. The RARECARE project, based on data provided by 90 CRs in 22 European countries, gives a unique opportunity to study the epidemiology of rare tumours in a large population from various countries. RARECARE gathered CRs data on patients diagnosed from 1978 up to 2002, with vital status information available up to 31st December 2003 or later. To our knowledge, no similar large-scale analyses of rare tumours have been reported. The aim of this report is to provide the estimation of indicators of rare tumours in Europe. Therefore, incidence, prevalence, survival and mortality estimates of rare cancer cases diagnosed in 1995-2002 are reported.

MATERIALS

Selection of CRs and population coverage

Table 1 lists the 90 CRs, with their population coverage, which participated to the EURO CARE project [website <http://www.eurocare.it/>], estimating the survival of cancer patients in Europe, and accepted to participate also to the RARECARE project. Seventy-eight CRs from 22 European countries contributed data on cancers diagnosed in both children (0–14 years) and adults (15–99 years): of these, four CRs were specialized collecting data only for a specific cancer site, and 8 CRs contributed data for a set of selected cancer sites for whom follow-up status was completed. Furthermore, 10 CRs contributed data on childhood cancers only (Table 1). Twelve European countries have national cancer registration: Austria, Finland, Iceland, Ireland, Malta, Norway, Slovakia, Slovenia, Sweden, Northern Ireland, Scotland and Wales. Germany and England have national coverage for childhood cancers only. The remaining countries have CRs covering between 8% and 58% of their

populations, with the conspicuous exception of Germany, where only 1.3% of the adult population is covered. The mean population covered over the period 1995–1999 was about 162,000,000, corresponding to 39% of the population of the countries participating in RARECARE and 32% of the population of the European Union (EU27). Data from the *10 specialized childhood cancer* registries were not analysed because our focus is on the entities that are rare over the entire population. The 12 CRs providing data only for selected cancer sites were also removed due to the difficulty to precisely determine which of the entities defined by RARECARE belongs to the incidence series collected by these CRs. Data from *Finland* were excluded from the systematic analyses carried out for the estimation of burden indicators, because morphology was not coded according to ICD-O classification, so making it impossible to attribute most diagnoses to a specific cancer entity; Tyrol CRs was excluded as well to avoid overlaps with the national Austrian registry; UK England national *dataset* was also excluded to analyse the longer data series provided by local England CRs. Finally, 65 out of the above 90 CRs were included in the present analysis. A total of 4,093,062 of cancer cases were then analyzed (Table 2). The classification of cancer cases used in this project is the International Classification of Diseases for Oncology 3rd version (ICD-O3) [2]. Table 2 presents number of cancers cases, together with indicators of data quality by CRs.

Rare tumours selection

A list of tumours (frequent and rare), reporting the number of cases and the crude incidence rate was built and it is available on the project website: <http://www.rarecare.eu/rarecancers/rarecancers.asp>. This list was hierarchically structured in three Layers based on various combinations of ICD-O morphology and topography [2]:

Layer 1) families of tumours relevant for the Health Care Organization;

Layer 2) tumours defined in a clinically sound way (perceived by clinicians as single diseases and relevant for clinical decision making and research);

Layer 3) single WHO tumour entities.

Rare tumours were identified as those included within the 1st or the 2nd layer and having an incidence rate less than 6/100,000/year. This annual threshold resulted in 194 tumour entities, which were then considered rare tumours.

CRs data quality analysis

Automated procedures checked each data field and combinations of fields in each case record. Topographies and morphologies were checked against ICD-O3 lists, and records with invalid codes were excluded [3,4]. Other checks were carried out on combinations of data fields. They concerned:

- Consistency between dates of birth, diagnosis and follow-up.
- Consistency of site–morphology combinations. Both standard IARC routines [4] and those additionally defined by the EURO CARE protocol [5, 3] were used.
- Consistency of age–site, age–morphology, sex–site and sex–morphology combinations. Unlikely combinations were checked against IARC criteria [4].
- Consistency of morphology–behaviour combinations. Combinations not listed in ICD-O-3 classification were flagged as unlikely, but the corresponding records were used in the analysis.

A more detailed description of the procedure of the data quality check is available in the paper by De Angelis et al [5].

Estimation of incidence rates can be biased by the inclusion of registries with insufficient quality of topographical and (mainly) morphological information on diagnoses. In these registries, specific rare tumours may not be precisely recognized and a certain number of patients may have their cancer classified within a wider, not clearly specified category (such as carcinoma NOS, Lymphoma NOS, etc). Two possible criteria were identified for testing the quality of the RARECARE data: proportion of cases with non specified morphology, and unexpectedly low incidence of rare tumours, suggesting insufficient specificity of diagnosis. For each CR, the proportion of cases with non specified morphology was calculated with the following morphology codes: 8000 (cancer), 8001 (cancer cells) and 9590 (malignant lymphoma, NOS). These codes are excluded from the definition of any Layer 2 entity in the rare tumour list. The results are shown in Table 3. None of the registries show clearly outlier values. Fixing a cut point at 20%, 5 CRs were identified to be

potentially removed from the analysis for having a higher proportion of unspecified morphology cases. Rare tumours are defined by combinations of topography and morphology codes. While the former are widely used in the analysis of CR data and can be considered as sufficiently reliable and precise, there is less experience in the precision of morphology coding across registries. Coding with a more general term such as 8010 or 8140 can result in cases attributed to a Layer 1 group of entities but not to a specific Layer 2 rare entity. Therefore, for each registry, total incidence calculated for all Layer 1 entities combined should be higher than incidence calculated for all Layer 2 entities combined. The difference can be taken as an indicator of the proportion of poorly specified morphology codes. This analysis is reported in Table 3 (columns 5-7). Using also here a cut point of 20 percent difference, four additional registries to be potentially removed from the analysis were identified. A final analysis was focused on the registry sensitivity, defined as the proportional difference in incidence obtained by the removal of each single registry from the data in analysis (Table 3 column 8). For the reasons expressed above, positive values may be due to lower data quality, indicating that the registry data tends to lower the pooled incidence estimate. These data are quite reassuring: only one registry has a value greater than 1%, and four a value greater than 0.5%. In conclusion, incidence of all the entities was calculated both with and without the nine above selected registries. The results did not change substantially, with only one entity changing from rare to not rare category.

Therefore, none of the 65 RARECARE CRs was finally excluded from the analysis.

METHODS

Burden indicators

Statistical analysis was principally made by SEER*STAT software, (Surveillance Research Program, National Cancer Institute www.seer.cancer.gov/seerstat), version 6.5.1. Mixture model survival analysis was carried out by SAS NLIN procedure.

For all the tumours, defined by the RARECARE project, incidence, prevalence, mortality rates and relative survival were calculated. The corresponding statistical methods used for the analysis of the burden indicators follow:

- *Incidence* - Crude, and age specific incidence rates were estimated dividing the number of incident cases (period of diagnosis 1995-2002) for a given entity, by

the corresponding person-years lived from the general population calculated during the same period. All newly diagnosed cases were selected, with the inclusion of second primary and “death certificate only” (DCO) cases, but the exclusion of cases incidentally discovered at autopsy. For geographical comparisons, age standardized rates were computed to adjust for different age distribution of the compared populations, using the conventional European standard population.

- *Prevalence* - The number of cancer survivors and their proportion per 100,000 population has been estimated at the index date of 1st January 2003. The counting method [6], based on CRs incidence and follow-up data, has been applied to CRs data from 1988 to 2002. The method consists in enumerating how many persons previously diagnosed with a given cancer are alive at the defined index date. Of course, it is not possible to trace back all the cancers diagnosed before the start of registration activities. Since most European CRs started registration activities during the 1980s, a common starting point for the analysis was then stated at 1st January 1988. Only 22 CRs covered the entire period providing 15 years prevalence and were therefore included in the analysis (Table 4). Multiple tumours were included in the prevalence estimates of all the corresponding entities. DCO and autoptic cases were by definition excluded. The life status of cases lost to follow-up or censored before the index date was estimated from the survival probability between the censoring and the index dates, derived from a subset of cancer patients matched by age and cancer grouping (layer 1). In this way an estimate of 15-year prevalence was obtained, disentangled by time since diagnosis. In this report, only 15-year prevalence is provided. The completeness index method [7] will be used to estimate complete prevalence, adding the number of prevalent cases who were diagnosed before the start of cancer registration in a given territory.
- *Mortality* - Mortality data do not exist for most of the defined rare entities, because morphology is not included in information provided by official death records. In this report, mortality rates were estimated from incidence rates multiplied by the fatality proportion, under the assumption of constant incidence and survival rates. Mixture models [8] have been applied to relative survival data of patients diagnosed during the period 1988-1999. This class of survival models (also addresses as “cure”) models, assume that a proportion of cases (those cured)

has the same mortality rate of the general population, while the complementary fraction (the “fatal” cases) have an excess death rate attributed to the diagnosed cancer. Mixture models allow then to estimate the proportion of patients who die from their cancer. Mortality figures should be taken as indicative values, mainly for purposes of comparison with other (non cancer) rare diseases [9], for which official mortality is the only data source available.

- *Relative Survival* - Relative survival was estimated according to the Hakulinen method [10]. Standard survival estimates, based on cohort of diagnosis, were obtained for patients diagnosed during the period 1995-1999 and followed-up until, at least, the end of 2003. All patients diagnosed during this period were selected, with the exception of DCO and autoptic cases. Cases lost to follow-up before the end of the year 2003 were right censored at the time of the last vital status information. Period survival indicators for the years 2000-2002 were also estimated using the Brenner algorithm [11]. Both estimates are given by years since diagnosis.
- *Stratified Analysis* - Incidence, prevalence and mortality rates are estimated also by sex and four age strata (<15, 15-24, 25-64, 65+). To assist in geographical comparison across Europe, the above indicators, as well as survival, will be presented by region (Northern Europe, Central Europe, Eastern Europe, Southern Europe, UK and Northern Ireland, overall EU), and by mean of two macro-economic indicators: the Gross Domestic Product (GDP) and the Total National Expenditure on Health (TNEH) in 1994-2002 [12]. Macro economic indicators were grouped into three categories: Low GDP 0-20000 US\$ PPP (Purchasing Power Parity), Middle GDP >25000 US\$ PPP and High GDP >25000 US\$ PPP; low TNEH 0-1500 US\$ PPP, middle TNEH >1501-2250 US\$ PPP and high TNEH >2250 US\$ PPP. For each burden indicator, 95% confidence intervals are given as well. A bar graph showing 5-year relative survival (cohort and period) by region is also given per each tumour entity.

RESULTS

Table 5 shows incidence, prevalence and mortality indicators for all the tumours defined by the RARECARE project. Table 6 shows the same indicators for the group of big families of rare tumours which correspond to the Layer 1 of the list. Two

hundred and sixty tumour entities are listed in Table 5, of those, 194 are rare (i.e. have an incidence rate $\leq 6/100,000$).

Incidence

For the majority (83.0%) of the rare entities, the annual incidence was lower than 1 per 100,000. The annual incidence of the other rare tumours was between 1 and <2, between 2 and <3 and between 3 and < 6 for 12, 5 and 10 rare tumours respectively.

Prevalence

Fifteen-year prevalence for all the rare tumours was $\leq 50/100,000$, that is the cut off utilized in Europe for the definition of rare diseases. By contrast, Epithelial Tumours of Hypopharynx and Larynx, Oesophagus, Stomach, Pancreas, Liver and IBT, and Ovary have prevalence rates lower than 50 per 100,000 but annual incidence rates higher than 6 per 100,000. These tumours are then classified as frequent according to our incidence-based definition, but rare according to the standard EU prevalence-based criterion. All these tumours have very poor survival and therefore low prevalence figures, even in presence of a relatively high risk of occurrence, at least for the European population.

Mortality

Similarly to the incidence, the estimated annual mortality rates were lower than 1 per 100,000 for the majority of the rare tumours (89%). The estimated annual mortality rates were lower than crude incidence rates and the mortality incidence rates ratio (M/I) were between 1 and 0.00. The closer a M/I value is to 1.0 the worse is the expected outcome. In our results, among rare tumours M/I value closer to 1 (≥ 0.8) were found for the epithelial tumours of the oropharynx, of the gallbladder, of the trachea, of the thymus, for the adnexal carcinoma of the skin, malignant mesothelioma, sarcoma of Kaposi, glial tumours of the CNS, acute myeloid leukaemia, myeloproliferative neoplasms and for myelodysplastic myeloproliferative diseases.

Relative survival

Table 7 shows the cohort and period relative survival for all the tumours defined as rare.

Five-year relative survival of patients diagnosed in 1995-1999 was equal or more than 50% for the majority of the rare tumours (Table 7). Among rare cancers, survival was poor (<20%) for the Epithelial Tumours of the Gallbladder, Trachea, Mesothelioma and Acute Myeloid Leukaemia. Also, it was poor for some rare tumours of frequent tumour families such as Squamous Cell tumour of the Kidney, and some rare histotypes of the lung, the oesophagus and the pancreas. The highest 5-year survival figures (>90%) were observed for tumours of the testis (except the Epithelial Tumours), Pancreatoblastoma, Retinoblastoma, Paget disease of the vulva and vagina, the Epithelial and Soft tissue tumours of the skin (except adnexal carcinoma), nodular Hodgkin lymphoma (lymphocyte predominance), special types of adenocarcinoma of the breast, adenocarcinoma of the middle ear, the ependymal tumour of the nerves, autonomic nervous system and paraganglia and the squamous cell carcinoma and variants of the Lip. Up-to-date five-year relative survival, as estimated from 2000-2002 period survival analysis, was usually higher than 5-year cohort survival analysis.

Stratified Analysis

The results of the stratified analysis are presented in a dedicated Annex available on the web-site of the RARECARE project.

DISCUSSION

Bias in our results might arise because of variations in data quality and comparability. However, our major indicators of the quality of cancer-registry data—ie, proportion of cases reported as death-certificate only, microscopically verified cases and lost to follow-up—suggest a high-quality dataset (Table 2). More detailed analysis of the quality of registry data and comparability of diagnoses necessitates an in-depth analysis of cancer-registration documents, and possibly pathological review of all registered selected rare tumours, both of which are beyond the scope of this report. Inconsistencies in diagnostic and coding criteria can frequently be shown by unlikely geographical variation in incidence. We analysed the effect of low quality data for rare tumours CRs and we realised that the effect was very minor. Actually, a

dedicated WP is working on data quality revising a sample of selected rare tumours and the effect of this revision on incidence and survival rates will be calculated. A report based on these analyses will be prepared by the end of June, 2010 (Deliverable no.15).

The incidence for tumour entities is in general underestimated for Layer 2 entities because of the relatively high proportion of morphology codes NOS. The extreme effect is shown by the Layer 1 epithelial tumours of pancreas and oesophagus which are not rare, but include all Layer 2 entities with very low incidence rates, thus rare.

By contrast, Gastro intestinal stromal tumours (GIST), which is a 1st layer entity is underestimated owing to the fact that the specific ICD-O code was inexistent but has now been introduced in the ICD-O3.

With this report we are able to provide 15-year prevalence proportions and not complete prevalence one. We realized that for many cancers the difference between these two measures is relevant, separating rare and frequent according to the European definition of rare diseases. We are presently running all the necessary procedures that will enable to provide the complete prevalence for the rare entities.

Mortality is an important synthetic indicator, including both the risk to have a cancer and the risk to die after a cancer diagnosis. However, mortality for such a detailed entities is not provided by the national official statistics, because of the ICD classification utilized. Furthermore, for few European countries and several World wide countries, mortality is the only indicator of frequency available for between country-comparison. This is why we put a lot of effort for the estimation of rare tumours mortality.

In conclusion, according to our estimates, 2.5 millions of patients are living today with a diagnosis of rare cancers in Europe and every year there are 488,000 new diagnoses of malignant rare cancers which represent in total 19% of all malignant cancers diagnosed in Europe each year.

REFERENCES

1. Gatta G, Ciccolallo L, Kunkler I, et al. Survival from rare cancer in adults: a population –based study. *Lancet Oncology*, 2006; 7: 132-40.
2. International Classification of Diseases for the Oncology (ICD-O). Percy C, Fritz A, Jack A, Shanmugarathan S, Sobin L, Parkin DM, Whelan S. Third Edition, WHO 2000.
3. EUROCARE study web-site: <http://www.eurocare.it/> [accessed 03.06.08].
4. Ferlay J, Burkhard C, Whelan S, Parkin DM. Check and conversion programs for Cancer Registries. International Agency for Research on Cancer, Technical Report No. 42: Lyon (France); 2005. <<http://www.iacr.com.fr/TR42.htm>>.
5. De Angelis R, Francisci S, Baili P et al. The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis. *European Journal Of Cancer* 45 (2009) 909 –930
6. Capocaccia R., Colonna M., Corazziari I., et al.. Measuring cancer prevalence in Europe: the EUROPREVAL Project. *Annals of Oncology* 2002, 13: 831-839.
7. Capocaccia R., De Angelis R.: Estimating the completeness of prevalence based on cancer registry data. *Stat Med* 1997, 16: 425-440.
8. Verdecchia A., De Angelis R., Capocaccia R. et al.: The cure of colon cancer: results from the Eurocare Study. *Int J Cancer* 1998, 77: 322-329.
9. European Parliament and Council of the European Communities (1999). Decision No 1295/1999/EC of the European Parliament and of the Council of 29 April 1999 adopting a programme of Community action on rare diseases within the framework for action in the field of public health (1999 to 2003).
10. Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. *Biometrics* 1982;38:933–42.
11. Brenner H, Söderman B, Hakulinen T. Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland. *Int J Epidemiol* 2002;31:456–62.
12. Organisation for economic Co-operation and Development (OECD). OECD Health Data 2004, 1st edn. Paris: OECD, 2004.

TABLES

Table 1. Countries and cancer registries participating in RARECARE with mean population size covered by registration in 1995-1999 and proportion (%) of national population covered. Countries with nation-wide cancer registration in bold.

Country	Registry	Mean Population	% National Coverage	Country	Registry	Mean Population	% National Coverage
Austria	Austria (national)	7,963,020	100	Malta	Malta	373,866	100
	Tyrol	662,087	8.2	The Netherlands	Amsterdam	2,771,383	17.6
Belgium	Flanders	5,919,586	58.2		Eindhoven	964,196	6.1
Finland	Finland	5,130,979	100		North Netherlands	2,101,219	13.5
					Twente	1,142,533	7.3
France	Bas Rhin	1,009,792	1.7		<i>Dutch Registries</i>	<i>6,971,154</i>	<i>44.5</i>
	Calvados (a)	641,148	1.1	Norway	Norway	4,394,802	100
	Calvados digestive (b)	641,148	1.1	Poland	Cracow	738,796	1.9
	Côte d'Or digestive (b)	505,083	0.9		Kielce	1,183,001	3.1
	Côte d'Or haematol. (c)	505,083	0.9		Warsaw	1,616,103	4.2
	Doubs	497,493	0.8		<i>Polish Registries</i>	<i>3,537,900</i>	<i>9.2</i>
	Haut Rhin	700,241	1.2	Portugal	South Portugal	4,401,902	43.4
	Hérault	872,683	1.5	Slovak Republic	Slovakia	5,381,037	100
	Isère	1,076,495	1.8	Slovenia	Slovenia	1,985,998	100
	Loire Atlantique (d)	1,114,479	1.9	Spain	Albacete (g)	358,533	0.9
	Manche	480,850	0.8		Basque Country	2,094,584	5.3
	Marne & Ardennes (e)	857,539	1.5		Castellón (f)	460,454	1.2
	Somme	553,801	0.9		Girona	523,244	1.3
	Tarn	342,400	0.6		Granada (h)	808,926	2
	<i>French Registries</i>	<i>8,652,004</i>	<i>10.5 - 14.7</i>		Murcia	1,101,177	2.8
	Bretagne (k)	535,933	4.9		Navarra	531,028	1.3
	Lorraine (k)	455,294	4.1		Tarragona	578,478	1.5
	<i>French Registries (k)</i>	<i>991,228</i>	<i>9</i>		<i>Spanish Registries</i>	<i>6,456,423</i>	<i>12.2-16.3</i>
					Comunitat Valenciana (k)	405,460	6.5

Germany	Saarland	1,079,880	1.3		Spain RNTI (k)	774,395	12.4	
	Germany Berlin (k)	500,505	3.8		Spanish Registries (k)	1,179,855	18.9	
	Germany East (k)	2,142,038	16.3	Sweden	Sweden	8,840,065	100	
	Germany West (k)	10,473,996	79.7	Switzerland	Basel	435,638	6.1	
	German Registries (k)	13,116,539	100		Geneva	401,080	5.6	
Iceland	Iceland	270,581	100		Grisons (i)	224,742	3.2	
Ireland	Ireland	3,659,684	100		St. Gallen	512,538	7.2	
Italy	Alto Adige	456,085	0.8		Ticino	306,117	4.3	
	Biella	190,031	0.3		Valais	272,843	3.8	
	Ferrara	351,964	0.6		Zurich (j)	1,181,050	16.6	
	Firenze	1,155,529	2.0		Swiss Registries	3,334,008	27.1-46.8	
	Friuli V.G.	1,185,933	2.1	UK England	East Anglia (l)	2,682,456	5.4	
	Genova	917,278	1.6		North Western	4,142,732	8.4	
	Macerata	300,354	0.5		Northern & Yorkshire (m)	6,555,870	13.3	
	Modena	617,191	1.1		Oxford	2,665,408	5.4	
	Napoli	538,607	0.9		South West	6,574,540	13.3	
	Palermo (f)	1,241,727	2.2		Trent	4,791,608	9.7	
	Parma	394,148	0.7		West Midlands	5,265,109	10.7	
	Ragusa	294,574	0.5		English Registries	32,677,723	66.2	
	Reggio Emilia	441,490	0.8	UK	England and Wales (k)	10,028,100	100	
	Romagna	970,735	1.7	UK N. Ireland	Northern Ireland	1,667,784	100	
	Salerno	1,090,072	1.9	UK Scotland	Scotland	5,085,648	100	
	Sassari	470,264	0.8	UK Wales	Wales	2,900,615	100	
	Trento	456,629	0.8					
	Umbria	831,147	1.5					
	Varese	809,768	1.4					
	Veneto	1,991,191	3.5					
		Italian Registries	14,998,047	25.3-27.4				
		Marche (k)	189,046	2.3				
		Piedmont (k)	511,451	6.2				
		Italian Registries (k)	700,497	8.5				
					Mean population			
					European Countries in RARECARE			
				EU Members States in RARECARE*				
				162,319,789				
				154,320,398				
				39				
				32				

- (a) not include cancers of the digestive organs
 - (b) cancers of the digestive organs only
 - (c) haematological malignancies only
 - (d) colon, rectum, and female breast only
 - (e) thyroid only
 - (f) female breast only
 - (g) female breast and male lung only
 - (h) tongue, oral cavity, oropharynx, head and neck, oesophagus, stomach, colon, rectum, biliary tract, larynx, lung-bronchus-trachea, skin melanoma, breast, cervix, corpus uteri, Hodgkin disease, and non Hodgkin lymphoma only
 - (i) stomach, colon, rectum, lung-bronchus-trachea, skin melanoma, breast, cervix, and prostate only
 - (j) colorectum only
 - (k) specialised childhood (0-14 years) cancer registries
 - (l) mean population 1996-1999
 - (m) mean population 1998-1999
- * 27 EU members

Table 2. Data quality indicators of all malignant cancers in European cancer registries included in the analysis, cases diagnosed 1995-2002.

Country	Registry	Number of malignant cancers	Data quality indicators					
			Death certificate only	Autopsy	Microscopic verification	Cases 1995-1998 censored before five years	Morphology code NOS *	Topography code NOS *
		N	(%)	(%)	(%)	(%)	(%)	(%)
Austria	Austria	304,493	8.9	0.0	85.2	12.1	10.13	0.56
Belgium	Flanders	144,715	0.0	0.2	89.8	0.0	7.34	0.54
France	Bas Rhin	13,113	0.0	0.0	95.8	0.6	3.91	0.21
	Doubs	5,742	0.0	0.0	95.8	0.9	3.24	0.30
	Haut Rhin	9,073	0.0	0.0	96.4	0.2	2.94	0.12
	Hérault	10,505	0.0	0.0	n.a.	0.1	1.49	0.10
	Isère	12,526	0.0	0.0	94.1	0.2	4.14	0.12
	Manche	6,267	0.0	0.0	96.5	2.2	3.37	0.34
	Somme	6,481	0.0	0.0	94.2	0.9	5.49	0.76
	Tarn	4,935	0.0	0.0	93.8	0.0	5.86	1.32
Germany	Saarland	54,132	3.9	0.0	91.8	12.1	7.96	0.55
Iceland	Iceland	8,854	0.1	1.4	96.6	0.0	3.47	0.01
Ireland	Ireland	156,529	2.0	0.3	86.7	0.0	11.02	0.67
Italy	Alto Adige	18,676	0.7	0.0	89.5	0.0	9.18	0.50
	Biella	11,770	1.3	0.4	87.0	0.0	12.51	0.33
	Ferrara	23,740	1.1	0.0	88.1	0.1	9.65	0.59
	Firenze	66,097	0.9	0.1	80.4	0.7	17.67	0.80
	Friuli V.G.	78,882	0.6	1.9	91.0	0.0	9.79	2.06
	Genova	44,207	1.8	0.0	81.4	0.0	16.57	0.92
	Macerata	10,396	1.3	0.0	87.4	0.2	13.05	0.61
	Modena	34,947	0.5	0.0	88.6	0.0	11.77	0.51
	Napoli	8,145	3.9	0.0	73.0	0.1	17.63	1.38
	Parma	23,836	1.0	0.0	86.0	0.0	13.10	0.68

	Ragusa	10,687	1.9	0.8	80.9	0.2	24.60	0.60
	Reggio Emilia	22,152	0.2	0.0	88.1	0.0	13.80	0.48
	Romagna	60,667	2.4	0.0	87.9	0.0	12.32	0.51
	Salerno	26,917	2.5	0.0	77.5	0.7	23.65	1.05
	Sassari	18,084	2.9	0.2	84.4	0.0	16.41	0.67
	Trento	17,788	2.0	0.0	85.0	0.0	27.82	3.83
	Umbria	45,221	0.7	0.0	84.0	0.0	12.61	0.56
	Varese	24,728	1.1	0.0	89.0	14.1	10.81	0.43
	Veneto	84,528	1.5	0.2	87.5	0.0	13.69	1.73
Malta	Malta	9,848	1.9	0.1	87.6	0.0	12.89	0.74
Norway	Norway	197,240	1.0	0.4	93.1	0.0	6.68	0.58
Poland	Cracow	24,545	1.1	0.1	75.2	3.8	27.17	1.20
	Kielce	34,123	0.0	0.0	80.2	0.0	21.73	0.96
	Warsaw	50,238	3.4	0.0	80.2	0.5	19.06	0.75
Portugal	South Portugal	32,917	0.0	0.0	93.9	0.0	7.22	0.39
Slovakia	Slovakia	128,686	12.8	1.5	81.8	1.0	17.93	1.65
Slovenia	Slovenia	56,632	1.6	1.1	90.8	0.1	9.61	0.67
Spain	Basque Country	44,809	4.2	0.0	86.3	0.0	11.43	0.68
	Girona	19,936	3.8	0.1	87.7	0.0	12.83	0.65
	Murcia	14,068	3.5	0.1	88.0	1.2	11.07	1.04
	Navarra	15,381	2.2	0.6	90.9	0.0	7.57	0.40
	Tarragona	12,412	4.8	0.0	86.4	0.0	13.33	0.73
Sweden	Sweden	347,616	0.0	2.2	98.2	0.0	2.62	1.25
Switzerland	Basel	13,654	0.0	4.3	99.0	5.5	0.23	0.01
	Geneva	16,775	0.5	1.1	92.6	0.0	6.18	0.74
	St. Gallen	16,588	0.7	1.2	92.8	0.3	4.39	0.41
	Ticino	10,784	3.0	0.3	91.4	0.0	6.82	1.40
	Valais	4,533	1.5	0.4	91.2	0.6	8.23	0.88
Netherlands	Amsterdam	95,439	0.0	0.5	95.7	1.2	4.24	0.10
	Eindhoven	27,985	0.0	0.0	95.7	0.0	4.14	0.15
	North Netherlands	58,508	0.0	1.0	94.7	0.0	5.29	0.22
	Twente	41,217	0.0	0.7	95.1	0.0	5.06	0.34
UK England	East Anglia	131,829	0.5	0.9	86.4	21.4	0.63	0.27

	Northern&Yorkshire	265,499	1.1	0.4	86.8	0.0	3.87	0.25
	Oxford	85,848	0.8	0.4	88.8	0.0	0.38	0.48
	South Western	168,672	7.8	0.1	70.2	0.0	10.58	1.25
	Trent	109,768	7.3	0.0	74.0	0.0	2.44	0.76
	West Midlands	190,726	5.1	1.1	81.9	0.0	4.19	0.40
UK N.								
Ireland	Northern Ireland	69,558	1.2	0.4	83.4	0.0	16.68	0.60
UK Scotland	Scotland	263,710	0.9	0.1	86.4	0.0	5.81	0.55
UK Wales	Wales	120,606	12.7	0.0	51.0	0.0	6.27	0.81
RARECARE		4,093,062	3.3	0.6	85.8	1.9	8.43	0.73

§ Microscopic verifications only partially available to the Wales CR.

Morphology and topography codes are M8000-8001 and C260, C268, C269, C390, C398, C399, C559, C579, C639, C689, C729, C759-C765, C767-C768 respectively.

n.a.: not available

Table 3. Quality analysis of topographical and morphological information on diagnoses.

Country	Registry	% of unspecified morphology cases	Incidence Layer 1	Incidence Layer 2	Diff. %	Sensitivity
Austria	Austria	10.13	463.6	375.0	19.1	0.00
Belgium	Flanders	7.34	465.7	389.4	16.4	0.62
France	Bas Rhin	3.91	420.3	392.4	6.7	0.49
	Doubs	3.24	372.7	348.5	6.5	0.09
	Haut Rhin	2.94	422.2	376.8	10.8	0.02
	Herauld	1.49	395.0	376.6	4.6	0.13
	Isère	4.14	377.8	350.4	7.3	0.07
	Manche	3.37	416.3	394.5	5.2	0.16
	Somme	5.49	368.1	334.1	9.2	-0.02
	Tarn	5.86	341.2	317.9	6.8	-0.03
Germany	Saarland	7.96	606.4	528.6	12.8	1.05
Iceland	Iceland	3.47	391.5	369.1	5.7	-0.03
Ireland	Ireland	11.02	499.3	431.7	13.5	-0.92
Italy	Alto Adige	9.18	492.6	437.6	11.2	0.03
	Biella	12.51	752.6	656.1	12.8	0.08
	Ferrara	9.65	819.9	721.6	12.0	0.36
	Firenze	17.67	679.2	542.1	20.2	0.27
	Friuli V.G.	9.79	795.4	674.6	15.2	0.56
	Genova	16.57	773.3	614.0	20.6	0.26
	Macerata	13.05	667.8	557.5	16.5	0.03
	Modena	11.77	675.7	591.5	12.5	0.42
	Napoli	17.63	279.4	212.5	23.9	0.11
	Parma	13.10	728.2	608.5	16.4	0.19
	Ragusa	24.60	434.9	321.4	26.1	0.04
	Reggio Emilia	13.80	680.1	557.8	18.0	-0.01

	Romagna	12.32	753.2	649.6	13.8	0.15
	Salerno	23.65	389.8	285.1	26.9	-0.36
	Sassari	16.41	458.2	377.8	17.5	0.00
	Trento	27.82	570.7	435.5	23.7	0.02
	Umbria	12.61	662.8	541.9	18.2	-0.03
	Varese	10.81	588.6	500.9	14.9	0.00
	Veneto	13.69	679.1	568.9	16.2	0.47
Malta	Malta	12.89	305.7	255.8	16.3	-0.04
Norway	Norway	6.68	534.3	480.3	10.1	0.25
Poland	Cracow	27.17	382.8	259.8	32.1	0.13
	Kielce	21.73	317.6	231.1	27.2	-0.29
	Warsaw	19.06	360.9	269.3	25.4	-0.23
Portugal	South Portugal	7.22	361.5	313.0	13.4	-0.09
Slovenia	Slovenia	17.93	340.3	288.7	15.2	-0.04
Slovakia	Slovakia	9.61	285.4	228.2	20.0	-1.19
Spain	Basque Country	11.43	399.5	343.1	14.1	-0.10
	Girona	12.83	440.1	381.0	13.4	0.17
	Murcia	11.07	306.1	260.8	14.8	-0.12
	Navarra	7.57	559.1	511.6	8.5	0.10
	Tarragona	13.33	402.1	336.1	16.4	-0.03
Sweden	Sweden	2.62	468.2	434.3	7.3	0.24
Switzerland	Basel	0.23	439.4	428.5	2.5	0.35
	Geneva	6.18	501.3	454.3	9.4	0.00
	St. Gallen	4.39	389.4	358.4	8.0	-0.05
	Ticino	6.82	480.9	436.0	9.3	0.06
	Valais	8.23	400.1	361.5	9.6	-0.03
Netherlands	Amsterdam	4.24	406.4	377.2	7.2	1.25
	Eindhoven	4.14	393.3	361.1	8.2	-0.23
	North Netherlands	5.29	389.4	359.9	7.6	0.09
	Twente	5.06	431.4	386.4	10.4	-0.11
UK England	East Anglia	0.63	597.1	529.0	11.4	-0.04
	Northern&Yorkshire	3.87	575.4	499.4	13.2	-0.63
	Oxford	0.38	376.4	319.0	15.2	-0.89

	South Western	10.58	476.0	353.1	25.8	-0.48
	Trent	2.44	426.4	327.6	23.2	-0.55
	West Midlands	4.19	424.6	345.6	18.6	-1.26
	Northern Ireland	16.68	485.3	391.4	19.3	-0.62
UK Scotland	Scotland	5.81	619.3	532.0	14.1	0.16
UK Wales	Wales	6.27	497.3	357.7	28.1	-0.13
RARECARE		8.43	481.3	406.7	15.5	

Table 4. Cancer registries included in the prevalence analysis.

Austria	Norway	<i>Netherlands</i>
<i>Germany</i>	<i>Poland</i>	Amsterdam
Saarland	Cracow	<i>UK England</i>
Iceland	Warsaw	East Anglia
<i>Italy</i>	Slovenia	Northern and Yorkshire
Firenze	Slovakia	Oxford
Modena	Sweden	West Midlands
Parma	<i>Switzerland</i>	Scotland
Ragusa	Geneva	UK Wales
Romagna		

Table 5. Crude annual incidence and mortality rate and prevalence proportion by tumour entities. Rates and proportions are per 100,000

	Tumour entities	Incidence				Prevalence				Mortality			
		N. of cases	Crude rate	Lower	Upper	N. of cases	Crude rate	Lower	Upper	N. of cases	Crude rate	Lower	Upper
				95%				95%				95%	
R	EPITHELIAL TUMOURS OF THE NASAL CAVITY AND SINUSES	3,594	0.44	0.43	0.46	1,453	2.27	2.15	2.39	2,221	0.27	0.27	0.28
	Squamous cell carcinoma and variants of the Nasal Cavity and Sinuses	2,515	0.31	0.3	0.32	1,049	1.64	1.54	1.74	1,556	0.19	0.19	0.20
R	Lymphoepithelial carcinoma of the Nasal Cavity and Sinuses	20	0.00	0.00	0.00	5	0.01	0.00	0.02	11	0.00	0.00	0.00
R	Undifferentiated carcinoma of the Nasal Cavity and Sinuses	142	0.02	0.01	0.02	61	0.10	0.07	0.12	117	0.02	0.01	0.02
R	Intestinal type adenocarcinoma of the Nasal Cavity and Sinuses	20	0.00	0.00	0.00	9	0.01	0.01	0.03	11	0.00	0.00	0.00
R	EPITHELIAL TUMOURS OF THE NASOPHARYNX	3,618	0.45	0.43	0.46	1,398	2.18	2.07	2.30	2,385	0.30	0.28	0.30
	Squamous cell carcinoma and variants of the Nasopharynx	2,657	0.33	0.32	0.34	1,098	1.71	1.61	1.82	1,685	0.21	0.20	0.22
R	Papillary adenocarcinoma of the Nasopharynx	7	0.00	0.00	0.00	3	0.00	0.00	0.01	3	0.00	0.00	0.00
R	EPITHELIAL TUMOURS OF THE MAJOR SALIVARY GLANDS AND SALIVARY GLAND TYPE TUMORS	10,633	1.31	1.29	1.34	5,570	8.70	8.48	8.93	4,906	0.60	0.60	0.62
	Epithelial tumours of the major salivary glands	5,919	0.73	0.71	0.75	3,256	5.09	4.91	5.27	2,778	0.34	0.33	0.35
R	Salivary gland type tumours of the Head and Neck	3,492	0.43	0.42	0.45	1,984	3.10	2.97	3.24	1,729	0.21	0.21	0.22
R	EPITHELIAL TUMOURS OF THE HYPOPHARYNX AND LARYNX	51,000	6.29	6.23	6.34	19,578	30.59	30.16	31.02	30,666	3.78	3.75	3.81
	Squamous cell carcinoma and variants of the Hypopharynx	9,633	1.19	1.16	1.21	1,960	3.06	2.93	3.20	8,196	1.01	0.99	1.03
R	Squamous cell carcinoma and variants of the Larynx	37,851	4.67	4.62	4.71	16,553	25.86	25.47	26.26	20,746	2.56	2.53	2.58
R	EPITHELIAL TUMOURS OF THE OROPHARYNX	22,337	2.75	2.72	2.79	7,330	11.45	11.19	11.72	19,412	2.39	2.36	2.42
	Squamous cell carcinoma and variants of the Oropharynx	21,012	2.59	2.56	2.63	7,059	11.03	10.77	11.29	18,313	2.26	2.23	2.29
	EPITHELIAL TUMOURS OF THE ORAL CAVITY AND LIP	38,892	4.8	4.75	4.84	16,846	26.32	25.93	26.72	NE	NE	NE	NE

R	Squamous cell carcinoma and variants of the Oral cavity	26,720	3.3	3.26	3.33	10,166	15.88	15.58	16.20	20,668	2.55	2.52	2.58
R	Squamous cell carcinoma and variants of the Lip	9,894	1.22	1.20	1.24	6,092	9.52	9.28	9.76	3,273	0.40	0.40	0.41
	EPITHELIAL TUMOURS OF THE OESOPHAGUS	60,723	7.49	7.43	7.55	7,109	11.11	10.85	11.37	57,804	7.13	7.07	7.19
R	Squamous cell carcinoma and variants of the Oesophagus	27,525	3.39	3.35	3.43	3,155	4.93	4.76	5.11	26,190	3.23	3.19	3.26
R	Adenocarcinoma and variants of the Oesophagus	22,986	2.83	2.8	2.87	3,319	5.19	5.01	5.37	21,987	2.71	2.68	2.75
R	Salivary gland type tumours of the Oesophagus	47	0.01	0.00	0.01	4	0.01	0.00	0.02	45	0.01	0.00	0.01
R	Undifferentiated carcinoma of the Oesophagus	595	0.07	0.07	0.08	44	0.07	0.05	0.09	575	0.07	0.07	0.08
	EPITHELIAL TUMOURS OF THE STOMACH	151,346	18.66	18.57	18.76	26,764	41.82	41.32	42.32	128,769	15.88	15.80	15.96
F	Adenocarcinoma and variants of the Stomach	123,800	15.27	15.18	15.35	24,483	38.25	37.78	38.74	102,227	12.61	12.53	12.68
R	Squamous cell carcinoma and variants of the Stomach	1,049	0.13	0.12	0.14	144	0.23	0.19	0.27	1,014	0.13	0.12	0.14
R	Salivary gland type tumours of the Stomach	41	0.01	0.00	0.01	10	0.02	0.01	0.03	35	0.01	0.00	0.01
R	Undifferentiated carcinoma of the Stomach	1,361	0.17	0.16	0.18	176	0.28	0.24	0.32	1,248	0.16	0.15	0.17
	EPITHELIAL TUMOURS OF THE SMALL INTESTINE	5,882	0.73	0.71	0.74	1,305	2.04	1.93	2.15	4,691	0.58	0.57	0.59
R	Adenocarcinoma and variants of the Small Intestine	4,615	0.57	0.55	0.59	1,100	1.72	1.62	1.82	3,721	0.46	0.44	0.48
R	Squamous cell carcinoma and variants of the Small Intestine	51	0.01	0.00	0.01	11	0.02	0.01	0.03	39	0.00	0.00	0.00
	EPITHELIAL TUMOURS OF THE COLON	346,910	42.78	42.64	42.92	133,758	208.99	207.88	210.12	214,957	26.51	26.42	26.59
F	Adenocarcinoma and variants of the Colon	302,918	37.36	37.22	37.49	127,282	198.88	197.78	199.97	175,124	21.60	21.52	21.67
R	Squamous cell carcinoma and variants of the Colon	170	0.02	0.02	0.02	47	0.07	0.05	0.10	143	0.02	0.02	0.02
	EPITHELIAL TUMOURS OF THE RECTUM	138,806	17.12	17.03	17.21	60,099	93.90	93.15	94.66	95,392	11.77	11.70	11.83
F	Adenocarcinoma and variants of the Rectum	125,890	15.52	15.44	15.61	56,987	89.04	88.31	89.78	84,325	10.40	10.34	10.46
R	Squamous cell carcinoma and variants of the Rectum	600	0.07	0.07	0.08	315	0.49	0.44	0.55	364	0.04	0.04	0.05
R	Basaloid carcinoma of the Rectum	123	0.02	0.01	0.02	37	0.06	0.04	0.08	114	0.02	0.01	0.02
	EPITHELIAL TUMOURS OF THE ANAL CANAL	8,922	1.10	1.08	1.12	4,133	6.46	6.26	6.66	5,653	0.70	0.68	0.71
R	Squamous cell carcinoma and variants of the Anal Canal	4,982	0.61	0.60	0.63	2,815	4.40	4.24	4.56	2,742	0.34	0.33	0.35
R	Adenocarcinoma and variants of the Anal Canal	2,098	0.26	0.25	0.27	575	0.90	0.83	0.97	1,540	0.19	0.18	0.20
R	Basaloid carcinoma of the Anal Canal	993	0.12	0.11	0.13	507	0.79	0.72	0.86	627	0.08	0.07	0.08
R	Paget disease of the Anal Canal	32	0.00	0.00	0.01	13	0.02	0.01	0.03	20	0.00	0.00	0.01
	EPITHELIAL TUMOURS OF THE PANCREAS	95,836	11.82	11.74	11.89	4,936	7.71	7.50	7.93	93,658	11.55	11.47	11.62
F	Adenocarcinoma and variants of the Pancreas	61,459	7.58	7.52	7.64	3,740	5.84	5.66	6.03	60,227	7.43	7.37	7.49
R	Squamous cell carcinoma and variants of the Pancreas	211	0.03	0.02	0.03	19	0.03	0.02	0.05	198	0.03	0.02	0.03
R	Acinar cell carcinoma of the Pancreas	175	0.02	0.02	0.03	29	0.05	0.03	0.06	145	0.02	0.02	0.02
R	Mucinous cystadenocarcinoma of the Pancreas	65	0.01	0.01	0.01	19	0.03	0.02	0.05	39	0.01	0.01	0.01
R	Intraductal papillary mucinous carcinoma invasive of the Pancreas	5	0.00	0.00	0.00	3	0.00	0.00	0.01	3	0.00	0.00	0.00
R	Solid pseudopapillary carcinoma of the Pancreas	6	0.00	0.00	0.00	2	0.00	0.00	0.01	4	0.00	0.00	0.00

R	Serous cystadenocarcinoma of the Pancreas	1	0.00	0.00	0.00	0.00	0.00	0.00	0.01	1	0.00	0.00	0.00
R	Carcinoma with osteoclast-like giant cells of the Pancreas	0	NE	NE	NE	0	NE	NE	NE	0	NE	NE	NE
	EPITHELIAL TUMOURS LIVER AND INTRAHEPATIC BILE TRACT (IBT)	50,933	6.28	6.23	6.34	3,493	5.46	5.28	5.64	50,560	6.23	6.18	6.29
R	Hepatocellular carcinoma of the Liver and IBT	25,123	3.1	3.06	3.14	2,272	3.55	3.41	3.70	24,951	3.08	3.04	3.12
R	Cholangiocarcinoma of the IBT	6,761	0.83	0.81	0.85	462	0.72	0.66	0.79	6,717	0.82	0.80	0.84
R	Adenocarcinoma and variants of the Liver and IBT	1,688	0.21	0.20	0.22	119	0.19	0.15	0.22	1,681	0.21	0.20	0.22
R	Undifferentiated carcinoma of the Liver and IBT	131	0.02	0.01	0.02	5	0.01	0.00	0.02	125	0.02	0.01	0.02
R	Squamous cell carcinoma and variants of the Liver and IBT	92	0.01	0.01	0.01	8	0.01	0.01	0.02	74	0.01	0.01	0.01
R	Bile duct cystadenocarcinoma of the IBT	14	0.00	0.00	0.00	1	0.00	0.00	0.01	11	0.00	0.00	0.00
	EPITHELIAL TUMOURS GALLBLADDER AND EXTRAHEPATIC BILIARY DUCT (EBT)	35,840	4.42	4.37	4.47	3,940	6.16	5.96	6.35	33,298	4.11	4.06	4.15
R	Adenocarcinoma and variants of the Gallbladder and EBT	21,403	2.64	2.60	2.67	3,111	4.86	4.69	5.03	19,717	2.43	2.40	2.46
R	Combined hepatocellular carcinoma and cholangiocarcinoma of the Gallbladder and EBT	14	0.00	0.00	0.00	3	0.00	0.00	0.01	13	0.00	0.00	0.00
R	Squamous cell carcinoma of the Gallbladder and EBT	293	0.04	0.03	0.04	27	0.04	0.03	0.06	286	0.04	0.03	0.04
	EPITHELIAL TUMOURS OF THE TRACHEA	1,090	0.13	0.13	0.14	155	0.24	0.21	0.28	1,044	0.12	0.12	0.13
R	Squamous cell carcinoma and variants of the Trachea	663	0.08	0.08	0.09	72	0.11	0.09	0.14	648	0.08	0.08	0.09
R	Adenocarcinoma and variants of the Trachea	108	0.01	0.01	0.02	10	0.02	0.01	0.03	94	0.01	0.01	0.02
R	Salivary gland type tumours of the Trachea	79	0.01	0.01	0.01	49	0.08	0.06	0.10	79	0.01	0.01	0.01
	EPITHELIAL TUMOURS OF THE LUNG	454,883	56.10	55.93	56.26	49,225	76.91	76.23	77.59	432,572	53.35	53.19	53.50
F	Squamous cell carcinoma and variants of the Lung	109,474	13.50	13.42	13.58	14,571	22.77	22.40	23.14	101,951	12.57	12.50	12.65
F	Adenocarcinoma and variants of the Lung	83,764	10.33	10.26	10.4	12,661	19.78	19.44	20.13	78,403	9.67	9.60	9.73
R	Large cell carcinoma of the Lung	32,526	4.01	3.97	4.05	3,768	5.89	5.70	6.08	29,861	3.68	3.64	3.72
R	Well differentiated endocrine carcinoma of the lung	5,121	0.63	0.61	0.65	2,421	3.78	3.63	3.94	1,608	0.20	0.19	0.20
F	Poorly differentiated endocrine carcinoma of the Lung	62,293	7.68	7.62	7.74	5,032	7.86	7.65	8.08	60,938	7.51	7.45	7.57
R	Bronchiolo-alveolar carcinoma of the Lung	5,566	0.69	0.67	0.70	1,418	2.22	2.10	2.33	5,177	0.64	0.62	0.65
R	Salivary gland type tumours of the Lung	358	0.04	0.04	0.05	139	0.22	0.18	0.26	349	0.04	0.04	0.05
R	Sarcomatoid carcinoma of the Lung	1,137	0.14	0.13	0.15	196	0.31	0.26	0.35	1,104	0.14	0.13	0.15
R	Undifferentiated carcinoma of the Lung	7,951	0.98	0.96	1.00	736	1.15	1.07	1.24	7,689	0.95	0.93	0.97
	EPITHELIAL TUMOURS OF THE THYMUS	1,364	0.17	0.16	0.18	623	0.97	0.90	1.05	1,188	0.15	0.14	0.16
R	Malignant thymoma	1,119	0.14	0.13	0.15	546	0.85	0.78	0.93	1,033	0.13	0.12	0.14
R	Squamous cell carcinoma of the Thymus	38	0.00	0.00	0.01	9	0.01	0.01	0.03	33	0.00	0.00	0.00
R	Undifferentiated carcinoma of the Thymus	20	0.00	0.00	0.00	2	0.00	0.00	0.01	20	0.00	0.00	0.00
R	Lymphoepithelial carcinoma of the Thymus	6	0.00	0.00	0.00	5	0.01	0.00	0.02	5	0.00	0.00	0.00
R	Adenocarcinoma and variants of the Thymus	16	0.00	0.00	0.00	3	0.00	0.00	0.01	12	0.00	0.00	0.00
	EPITHELIAL TUMOURS OF THE BREAST	519,188	64.03	63.85	64.20	339,598	530.61	528.83	532.40	247,603	30.54	30.45	30.62

F	Invasive ductal carcinoma of the Breast	327,855	40.43	40.29	40.57	210,567	329.01	327.60	330.41	156,815	19.34	19.27	19.40
F	Invasive lobular carcinoma of the Breast	58,726	7.24	7.18	7.30	37,579	58.72	58.12	59.31	32,190	3.97	3.94	4.00
R	Mammary Paget's disease of the Breast	4,135	0.51	0.49	0.53	2,795	4.37	4.21	4.53	1,325	0.16	0.16	0.17
R	Special types of adenocarcinoma of the Breast	28,997	3.58	3.53	3.62	22,070	34.48	34.03	34.94	9,042	1.12	1.10	1.13
R	Metaplastic carcinoma of the Breast	495	0.06	0.06	0.07	263	0.41	0.36	0.46	339	0.04	0.04	0.05
R	Salivary gland type tumours of the Breast	426	0.05	0.05	0.06	252	0.39	0.35	0.45	368	0.04	0.04	0.05
R	Epithelial tumours of the Male Breast	3,835	0.97	0.94	1.00	1,896	6.09	5.82	6.37	1,812	0.46	0.44	0.47
	EPITHELIAL TUMOURS OF THE CORPUS UTERI	84,500	10.42	10.35	10.49	59,973	93.71	92.96	94.46	28,647	3.53	3.51	3.56
F	Adenocarcinoma and variants of the Corpus Uteri	77,394	9.54	9.48	9.61	56,676	88.56	87.83	89.29	24,123	2.97	2.95	3.00
	Squamous cell carcinoma and variants of the Corpus Uteri	945	0.12	0.11	0.12	392	0.61	0.55	0.68	579	0.07	0.07	0.07
R	Adenoid cystic carcinoma of the Corpus Uteri	11	0.00	0.00	0.00	81	0.13	0.10	0.16	2	0.00	0.00	0.00
R	Transitional cell carcinoma of the Corpus Uteri	1	0.00	0.00	0.00	2	0.00	0.00	0.01	0	NE	NE	NE
	EPITHELIAL TUMOURS OF THE CERVIX UTERI	49,259	6.07	6.02	6.13	37,713	58.93	58.33	59.52	20,984	2.59	2.56	2.61
	Squamous cell carcinoma and variants of the Cervix Uteri	34,703	4.28	4.23	4.32	26,833	41.93	41.43	42.43	14,367	1.77	1.75	1.79
R	Adenocarcinoma and variants of the Cervix Uteri	8,198	1.01	0.99	1.03	5,773	9.02	8.79	9.26	3,711	0.46	0.45	0.47
R	Undifferentiated carcinoma of the Cervix Uteri	203	0.03	0.02	0.03	105	0.16	0.13	0.20	168	0.02	0.02	0.02
	MIXED EPITHELIAL AND MESENCHYMAL TUMOURS OF THE UTERUS	3,613	0.45	0.43	0.46	1,304	2.04	1.93	2.15	2,597	0.32	0.31	0.33
	EPITHELIAL TUMOURS OF THE OVARY AND FALLOPIAN TUBE	76,284	9.41	9.34	9.47	28,525	44.57	44.05	45.09	61,632	7.60	7.55	7.65
R	Adenocarcinoma and variants of the Ovary	48,410	5.97	5.92	6.02	19,297	30.15	29.73	30.58	39,814	4.91	4.87	4.95
R	Mucinous adenocarcinoma of the Ovary	6,852	0.84	0.83	0.87	3,608	5.64	5.46	5.83	3,640	0.45	0.44	0.46
R	Clear cell adenocarcinoma of the Ovary	2,622	0.32	0.31	0.34	1,266	1.98	1.87	2.09	1,861	0.23	0.22	0.24
R	Adenocarcinoma and variants of the Fallopian tube	2,168	0.27	0.26	0.28	989	1.55	1.45	1.64	1,605	0.20	0.19	0.21
	NON EPITHELIAL TUMOURS OF THE OVARY	3,513	0.43	0.42	0.45	2,074	3.24	3.10	3.38	NE	NE	NE	NE
R	Mixed epithelial mesenchymal tumors of the Ovary	1,270	0.16	0.15	0.17	278	0.43	0.38	0.49	1,198	0.15	0.14	0.16
R	Sex cord tumours of the Ovary	1,088	0.13	0.13	0.14	824	1.29	1.20	1.38	629	0.08	0.08	0.08
R	Malignant Immature Teratomas of the Ovary	548	0.07	0.06	0.07	412	0.64	0.58	0.71	147	0.02	0.02	0.02
R	Germ cell tumours of the Ovary	607	0.07	0.07	0.08	560	0.87	0.80	0.95	79	0.01	0.01	0.01
	EPITHELIAL TUMOURS OF THE VULVA & VAGINA	15,522	1.91	1.88	1.94	7,374	11.52	11.26	11.79	8,049	0.99	0.97	1.01
	Squamous cell carcinoma and variants of the Vulva and Vagina	12,186	1.5	1.48	1.53	5,884	9.19	8.96	9.43	6,213	0.76	0.75	0.78
R	Adenocarcinoma and variants of the Vulva and Vagina	629	0.08	0.07	0.08	251	0.39	0.35	0.44	487	0.06	0.05	0.06
R	Paget disease of the Vulva and Vagina	414	0.05	0.05	0.06	248	0.39	0.34	0.44	414	0.05	0.05	0.06
R	Undifferentiated carcinoma of the Vulva and Vagina	65	0.01	0.01	0.01	24	0.04	0.02	0.06	50	0.01	0.01	0.01
	TROPHOBLASTIC TUMOURS OF THE PLACENTA	192	0.02	0.02	0.03	236	0.37	0.32	0.42	19	0.00	0.00	0.00
R	Choriocarcinoma of the Placenta	192	0.02	0.02	0.03	236	0.37	0.32	0.42	19	0.00	0.00	0.00

	EPITHELIAL TUMOURS OF THE PROSTATE	388,741	47.94	47.79	48.09	185,701	290.15	288.84	291.48	321,397	39.64	39.51	39.76
F	Adenocarcinoma and variants of the Prostate	328,962	40.57	40.43	40.71	170,016	265.65	264.38	266.91	271,482	33.48	33.37	33.60
R	Squamous cell carcinoma and variants of the Prostate	910	0.11	0.11	0.12	472	0.74	0.67	0.81	863	0.10	0.10	0.11
R	Infiltrating duct carcinoma of the Prostate	3,819	0.47	0.46	0.49	2,806	4.38	4.22	4.55	3,533	0.43	0.43	0.45
R	Transitional cell carcinoma of the Prostate	518	0.06	0.06	0.07	174	0.27	0.23	0.32	395	0.05	0.05	0.05
R	Salivary gland type tumours of the Prostate	13	0.00	0.00	0.00	4	0.01	0.00	0.02	10	0.00	0.00	0.00
	TUMOURS OF THE TESTIS AND PARATESTIS	25,510	3.15	3.11	3.18	26,722	41.75	41.25	42.26	3,154	0.39	0.38	0.39
R	Adenocarcinoma and variants of the Paratestis	12	0.00	0.00	0.00	6	0.01	0.00	0.02	8	0.00	0.00	0.00
R	Malignant Immature Teratomas of the Testis	6,748	0.83	0.81	0.85	7,424	11.60	11.34	11.87	1,128	0.14	0.14	0.14
R	Germ cell tumours Seminomatous of the Testis	14,089	1.74	1.71	1.77	14,560	22.75	22.38	23.12	1,014	0.13	0.12	0.13
R	Germ cell tumours non Seminomatous of the Testis	2,935	0.36	0.35	0.38	2,539	3.97	3.81	4.13	400	0.05	0.05	0.05
R	Trophoblastic tumours of the Testis	140	0.02	0.01	0.02	103	0.16	0.13	0.20	41	0.01	0.00	0.01
R	Sex Cord tumours of the Testis	178	0.02	0.02	0.03	144	0.22	0.19	0.26	30	0.00	0.00	0.00
	EPITHELIAL TUMOURS OF THE PENIS	5,058	0.62	0.61	0.64	2,635	4.12	3.96	4.28	1,877	0.23	0.23	0.24
R	Squamous cell carcinoma and variants of the Penis	4,649	0.57	0.56	0.59	2,423	3.79	3.64	3.94	1,847	0.23	0.22	0.23
R	Adenocarcinoma and variants of the Penis	40	0.00	0.00	0.01	16	0.02	0.01	0.04	31	0.00	0.00	0.01
	EPITHELIAL TUMOURS OF THE KIDNEY	85,671	10.56	10.49	10.64	37,169	58.08	57.49	58.67	63,861	7.87	7.82	7.93
F	Renal cell carcinoma and variants	67,788	8.36	8.3	8.42	34,419	53.78	53.21	54.35	49,198	6.07	6.02	6.11
R	Squamous cell carcinoma spindle cell type of the Kidney	56	0.01	0.01	0.01	8	0.01	0.01	0.02	51	0.01	0.01	0.01
R	Squamous cell carcinoma and variants of the Kidney	284	0.04	0.03	0.04	33	0.05	0.04	0.07	258	0.04	0.03	0.04
	EPITHELIAL TUMOURS OF THE PELVIS, URETER AND URETHRA	12,888	1.59	1.56	1.62	5,569	8.70	8.47	8.93	7,723	0.95	0.93	0.97
R	Transitional cell carcinoma of the Pelvis, Ureter and Urethra	11,139	1.37	1.35	1.4	5,021	7.85	7.63	8.07	6,520	0.80	0.79	0.82
R	Squamous cell carcinoma and variants of the Pelvis, Ureter and Urethra	417	0.05	0.05	0.06	114	0.18	0.15	0.21	377	0.05	0.05	0.05
R	Adenocarcinoma and variants of the Pelvis, Ureter and Urethra	301	0.04	0.03	0.04	119	0.19	0.15	0.22	258	0.03	0.03	0.03
R	Salivary gland type tumours of the Pelvis, Ureter and Urethra	2	0.00	0.00	0.00	1	0.00	0.00	0.01	1	0.00	0.00	0.00
	EPITHELIAL TUMOURS OF THE BLADDER	163,624	20.18	20.08	20.28	74,279	116.06	115.23	116.90	77,406	9.55	9.50	9.59
F	Transitional cell carcinoma of the Bladder	141,716	17.48	17.39	17.57	67,621	105.66	104.86	106.46	64,753	7.99	7.95	8.03
R	Squamous cell carcinoma and variants of the Bladder	3,436	0.42	0.41	0.44	851	1.33	1.24	1.42	2,272	0.28	0.27	0.29
R	Adenocarcinoma and variants of the Bladder	2,331	0.29	0.28	0.3	692	1.08	1.00	1.16	1,587	0.20	0.19	0.20
R	Salivary gland type tumours of the Bladder	9	0.00	0.00	0.00	2	0.00	0.00	0.01	5	0.00	0.00	0.00
	EPITHELIAL TUMOURS OF THE EYE AND ADNEXA	1,286	0.16	0.15	0.17	750	1.17	1.09	1.26	497	0.06	0.06	0.07
R	Squamous cell carcinoma and variants of the Eye Adnexa	304	0.04	0.03	0.04	139	0.22	0.18	0.26	118	0.02	0.01	0.02
R	Adenocarcinoma and variants of the Eye Adnexa	90	0.01	0.01	0.01	55	0.09	0.06	0.11	90	0.01	0.01	0.01

	EPITHELIAL TUMOURS OF THE MIDDLE EAR	245	0.03	0.03	0.03	103	0.16	0.13	0.19	161	0.02	0.02	0.02
R	Squamous cell carcinoma and variants of the Middle Ear	180	0.02	0.02	0.03	65	0.10	0.08	0.13	126	0.01	0.01	0.02
R	Adenocarcinoma and variants of the Middle Ear	29	0.00	0.00	0.01	22	0.03	0.02	0.05	19	0.00	0.00	0.01
	MALIGNANT MESOTHELIOMA	15,456	1.91	1.88	1.94	1,427	2.23	2.12	2.35	15,186	1.88	1.85	1.91
R	Mesothelioma of the pleura and pericardium	13,056	1.61	1.58	1.64	1,210	1.89	1.79	2.00	12,897	1.59	1.56	1.62
R	Mesothelioma of the peritoneum tunica vaginalis	1,014	0.13	0.12	0.13	112	0.17	0.14	0.21	986	0.13	0.12	0.13
F	MALIGNANT SKIN MELANOMA	100,883	12.44	12.36	12.52	79,245	123.82	122.96	124.68	31,572	3.89	3.87	3.92
R	MALIGNANT MELANOMA OF THE MUCOSA	4,132	0.51	0.49	0.53	1,059	1.66	1.56	1.76	3,250	0.40	0.39	0.42
R	MALIGNANT MELANOMA OF THE UVEA	5,301	0.65	0.64	0.67	3,306	5.17	4.99	5.35	2,242	0.27	0.27	0.28
	EPITHELIAL TUMOURS OF THE SKIN	397,503	49.02	48.87	49.17	257,623	402.53	400.98	404.09	NE	NE	NE	NE
F	Basal cell carcinoma of the Skin	263,713	32.52	32.4	32.65	176,685	276.07	274.78	277.36	1,258	0.16	0.15	0.16
F	Squamous cell carcinoma and variants of the Skin	132,597	16.35	16.26	16.44	80,506	125.79	124.92	126.66	23,454	2.89	2.88	2.91
R	ADNEXAL CARCINOMA OF THE SKIN	2,247	0.28	0.27	0.29	1,312	2.05	1.94	2.16	2,247	0.28	0.27	0.29
	EMBRYONAL NEOPLASMS	2,789	0.34	0.33	0.36	2,399	3.75	3.60	3.90	1,073	0.13	0.13	0.14
R	Neuroblastoma and ganglioneuroblastoma	982	0.12	0.11	0.13	628	0.98	0.91	1.06	632	0.08	0.07	0.08
R	Nephroblastoma	1,149	0.14	0.13	0.15	1,076	1.68	1.58	1.78	312	0.04	0.04	0.04
R	Retinoblastoma	437	0.05	0.05	0.06	539	0.84	0.77	0.92	0	NE	NE	NE
R	Hepatoblastoma	181	0.02	0.02	0.03	139	0.22	0.18	0.26	40	0.00	0.00	0.01
R	Pulmonary blastoma	34	0.00	0.00	0.01	13	0.02	0.01	0.03	7	0.00	0.00	0.00
R	Pancreatoblastoma	6	0.00	0.00	0.00	4	0.01	0.00	0.02	0	NE	NE	NE
	EXTRAGONADIC GERM CELL TUMOURS	1,028	0.13	0.12	0.13	687	1.07	0.99	1.16	396	0.05	0.05	0.05
R	Extragenadic malignant Immature Teratomas	337	0.04	0.04	0.05	202	0.32	0.27	0.36	153	0.02	0.02	0.02
R	Extragenadic Germ cell tumours	691	0.09	0.08	0.09	485	0.76	0.69	0.83	189	0.02	0.02	0.02
	SOFT TISSUE SARCOMA	38,527	4.75	4.7	4.8	18,335	28.65	28.23	29.07	23,756	2.93	2.90	2.96
R	Soft tissue sarcoma of the Head and Neck	2,356	0.29	0.28	0.3	1,183	1.85	1.74	1.96	1,276	0.16	0.15	0.16
R	Soft tissue sarcoma of the Limbs	8,376	1.03	1.01	1.06	4,821	7.53	7.32	7.75	4,489	0.55	0.54	0.57
R	Soft tissue sarcoma of the Superficial Trunk	3,824	0.47	0.46	0.49	1,503	2.35	2.23	2.47	2,497	0.31	0.30	0.32
R	Soft tissue sarcoma of the Mediastinum	218	0.03	0.02	0.03	35	0.06	0.04	0.08	180	0.02	0.02	0.02
R	Soft tissue sarcoma of the Heart	121	0.01	0.01	0.02	15	0.02	0.01	0.04	99	0.01	0.01	0.02
R	Soft tissue sarcoma of the Breast	1,513	0.19	0.18	0.20	902	1.41	1.32	1.51	648	0.08	0.08	0.09
R	Soft tissue sarcoma of the Uterus	4,035	0.5	0.48	0.51	2,005	3.13	3.00	3.27	2,621	0.32	0.31	0.33
R	Soft tissue sarcoma of the Genitourinary other	1,939	0.24	0.23	0.25	789	1.23	1.15	1.32	1,298	0.16	0.15	0.17
R	Soft tissue sarcoma of the other Viscera	4,129	0.51	0.49	0.52	1,339	2.09	1.98	2.21	3,351	0.41	0.40	0.42
R	Soft tissue sarcoma of the Paratesticular region	265	0.03	0.03	0.04	163	0.25	0.22	0.30	265	0.03	0.03	0.04
R	Soft tissue sarcoma of the Retroperitoneum and Peritoneum	2,344	0.29	0.28	0.30	674	1.05	0.98	1.14	2,147	0.27	0.26	0.27
R	Soft tissue sarcoma of the Pelvis	118	0.01	0.01	0.02	26	0.04	0.03	0.06	90	0.01	0.01	0.02
R	Soft tissue sarcoma of the Skin	2,514	0.31	0.3	0.32	1,724	2.69	2.57	2.82	550	0.07	0.07	0.07

R	Soft tissue sarcoma of the Paraorbital region	56	0.01	0.01	0.01	45	0.07	0.05	0.09	13	0.00	0.00	0.00
R	Soft tissue sarcoma of the Brain and other Nervous System	1,621	0.2	0.19	0.21	786	1.23	1.14	1.32	947	0.12	0.11	0.12
R	Embryonal rhabdomyosarcoma of the Soft Tissue	495	0.06	0.06	0.07	345	0.54	0.48	0.60	196	0.02	0.02	0.03
R	Alveolar rhabdomyosarcoma of the Soft Tissue	263	0.03	0.03	0.04	96	0.15	0.12	0.18	215	0.02	0.02	0.03
R	Ewing's family tumours of the Soft Tissue	193	0.02	0.02	0.03	100	0.16	0.13	0.19	135	0.01	0.01	0.02
	BONE SARCOMA	6,523	0.8	0.79	0.82	3,735	5.84	5.65	6.03	4,539	0.56	0.55	0.57
R	Osteogenic sarcomas	1,850	0.23	0.22	0.24	1,065	1.66	1.57	1.77	1,187	0.15	0.14	0.15
R	Chondrogenic sarcomas	1,982	0.24	0.23	0.26	1,268	1.98	1.87	2.09	962	0.12	0.11	0.13
R	Notochordal sarcomas, Chordoma	355	0.04	0.04	0.05	197	0.31	0.27	0.35	355	0.04	0.04	0.05
R	Vascular sarcomas, Angiosarcoma	26	0.00	0.00	0.00	7	0.01	0.00	0.02	24	0.00	0.00	0.00
R	Ewing's family of tumours	1,021	0.13	0.12	0.13	544	0.85	0.78	0.92	566	0.07	0.07	0.07
R	Epithelial tumours, Adamantinoma	70	0.01	0.01	0.01	39	0.06	0.04	0.08	25	0.00	0.00	0.00
R	Other high grade sarcomas (fibrosarcoma, malignant fibrous histiocytoma)	147	0.02	0.02	0.02	60	0.09	0.07	0.12	90	0.01	0.01	0.01
R	GASTROINTESTINAL STROMAL SARCOMA	536	0.07	0.06	0.07	224	0.35	0.31	0.40	305	0.04	0.03	0.04
R	KAPOSI SARCOMA	2,925	0.36	0.35	0.37	980	1.53	1.44	1.63	2,637	0.32	0.32	0.33
	NEURO ENDOCRINE TUMOURS	20,466	2.52	2.49	2.56	8,465	13.23	12.95	13.51	15,390	1.89	1.87	1.93
R	Well differentiated endocrine tumours, carcinoid	2,961	0.37	0.35	0.38	799	1.25	1.16	1.34	2,881	0.36	0.34	0.37
R	Well differentiated endocrine tumours, atypical carcinoid	6	0.00	0.00	0.00	3	0.00	0.00	0.01	4	0.00	0.00	0.00
R	Poorly differentiated endocrine carcinoma (lung microcytoma excluded)	4,225	0.52	0.51	0.54	575	0.90	0.83	0.98	3,528	0.43	0.43	0.45
R	Mixed endocrine-exocrine carcinoma	17	0.00	0.00	0.00	7	0.01	0.00	0.02	16	0.00	0.00	0.00
R	Endocrine carcinoma of the Thyroid gland	1,772	0.22	0.21	0.23	1,156	1.81	1.70	1.91	871	0.11	0.10	0.11
R	Well differentiated endocrine carcinoma not functioning of the Pancreas and of the Digestive tract	10,152	1.25	1.23	1.28	5,351	8.36	8.14	8.59	10,152	1.25	1.23	1.28
R	Well differentiated endocrine carcinoma functioning of the Pancreas and of the Digestive tract	200	0.02	0.02	0.03	96	0.15	0.12	0.18	112	0.01	0.01	0.02
R	Endocrine carcinoma of the Skin	1,082	0.13	0.13	0.14	449	0.70	0.64	0.77	457	0.05	0.05	0.06
	CARCINOMA OF ENDOCRINE ORGANS	33,757	4.16	4.12	4.21	23,316	36.43	35.96	36.90	NE	NE	NE	NE
R	Carcinomas of the Pituitary gland	333	0.04	0.04	0.05	300	0.47	0.42	0.52	316	0.04	0.04	0.05
R	Carcinomas of the Thyroid gland	29,803	3.68	3.63	3.72	21,639	33.81	33.36	34.26	16,220	2.00	1.98	2.02
R	Carcinomas of the Parathyroid gland	179	0.02	0.02	0.03	113	0.18	0.15	0.21	174	0.02	0.02	0.03
R	Carcinoma of the Adrenal gland	1,471	0.18	0.17	0.19	498	0.78	0.71	0.85	1,244	0.15	0.14	0.16
	GLIAL TUMOURS OF THE CENTRAL NERVOUS SYSTEM (CNS) AND PINEAL GLAND	43,344	5.35	5.29	5.4	9,286	14.51	14.21	14.81	41,208	5.09	5.03	5.13
R	Astrocytic tumours of the CNS	38,864	4.79	4.75	4.84	6,963	10.88	10.63	11.14	37,450	4.62	4.58	4.66
R	Oligodendroglial tumours of the CNS	2,863	0.35	0.34	0.37	1,266	1.98	1.87	2.09	2,863	0.35	0.34	0.37
R	Ependymal tumours of the CNS	1,617	0.2	0.19	0.21	1,056	1.65	1.55	1.75	988	0.12	0.12	0.13

	NON GLIAL TUMOURS OF THE CENTRAL NERVOUS SYSTEM (CNS) AND PINEAL GLAND	1,816	0.22	0.21	0.23	1,028	1.61	1.51	1.71	1,077	0.13	0.12	0.14
R	Embryonal tumours of the CNS	1,766	0.22	0.21	0.23	988	1.54	1.45	1.64	1,057	0.13	0.13	0.14
R	Choroid plexus carcinoma of the CNS	50	0.01	0.00	0.01	40	0.06	0.04	0.09	17	0.00	0.00	0.00
R	MALIGNANT MENINGIOMAS	1,225	0.15	0.14	0.16	769	1.20	1.12	1.29	826	0.10	0.09	0.11
	GLIAL TUMOURS OF THE OF THE NERVES, AUTONOMIC NERVOUS SYSTEM AND PARAGANGLIA	82	0.01	0.01	0.01	60	0.09	0.07	0.12	18	0.00	0.00	0.00
R	Astrocytic tumours of the Nerves, Autonomic Nervous System and Paraganglia	40	0.00	0.00	0.01	30	0.05	0.03	0.07	6	0.00	0.00	0.00
R	Ependymal tumours of the Nerves, Autonomic Nervous System and Paraganglia	42	0.01	0.00	0.01	30	0.05	0.03	0.07	0	NE	NE	NE
	NON-GLIAL TUMOURS OF THE OF THE NERVES, AUTONOMIC NERVOUS SYSTEM AND PARAGANGLIA	800	0.10	0.09	0.11	467	0.73	0.66	0.80	521	0.07	0.06	0.07
R	Embryonal tumours of the Nerves, Autonomic Nervous System and Paraganglia	599	0.07	0.07	0.08	354	0.55	0.50	0.61	400	0.05	0.05	0.05
R	Paraganglioma	201	0.02	0.02	0.03	113	0.18	0.14	0.21	138	0.01	0.01	0.02
	LYMPHOID DISEASES	236,546	29.17	29.05	29.29	99,405	155.32	154.35	156.29	226,766	27.96	27.85	28.08
R	Classical Hodgkin Lymphoma	19,318	2.38	2.35	2.42	14,652	22.89	22.52	23.27	8,414	1.04	1.02	1.05
R	Hodgkin lymphoma nodular lymphocyte predominance	469	0.06	0.05	0.06	305	0.48	0.42	0.53	253	0.03	0.03	0.03
R	Composite Hodgkin NHL	42	0.01	0.00	0.01	2	0.00	0.00	0.01	21	0.01	0.00	0.01
R	Precursor B/T lymphoblastic leukaemia/lymphoblastic lymphoma	10,384	1.28	1.26	1.31	6,295	9.84	9.59	10.08	6,205	0.76	0.75	0.78
R	Non Hodgkin Mature T cell and NK cell neoplasms	7,870	0.97	0.95	0.99	3,230	5.05	4.87	5.22	3,264	0.40	0.39	0.41
F	Non Hodgkin Mature B cell lymphoma	141,972	17.51	17.42	17.6	52,491	82.02	81.32	82.72	141,972	17.51	17.42	17.60
	ACUTE MYELOID LEUKAEMIA AND RELATED PRECURSOR NEOPLASMS	29,982	3.70	3.66	3.74	4,953	7.74	7.53	7.96	28,686	3.54	3.50	3.58
R	Acute Myeloid Leukemia with recurrent genetic abnormalities	921	0.11	0.11	0.12	376	0.59	0.53	0.65	901	0.11	0.11	0.12
R	Acute myeloid leukemia NOS (FAB or WHO type)	23,039	2.84	2.8	2.88	3,631	5.67	5.49	5.86	22,053	2.72	2.68	2.76
R	AML with myelodysplasia related and RAEBT-T	399	0.05	0.04	0.05	35	0.05	0.04	0.08	172	0.02	0.02	0.02
R	Therapy related myeloid neoplasms	9	0.00	0.00	0.00	2	0.00	0.00	0.01	8	0.00	0.00	0.00
R	Acute Myeloid Leukemia NOS and other AML	3,916	0.48	0.47	0.5	693	1.08	1.00	1.17	3,810	0.47	0.46	0.49
R	Myeloid sarcoma	124	0.02	0.01	0.02	29	0.05	0.03	0.07	43	0.01	0.00	0.01
R	Blastic plasmocytoid dendritic cell neoplasm*												
	MYELOPROLIFERATIVE NEOPLASMS	24,859	3.07	3.03	3.1	11,189	17.48	17.16	17.81	23,771	2.94	2.90	2.96
R	Chronic myeloid leukemia	10,185	1.26	1.23	1.28	3,087	4.82	4.65	5.00	10,185	1.26	1.23	1.28
R	Myelosclerosis with myeloid metaplasia	1,010	0.12	0.12	0.13	323	0.50	0.45	0.56	669	0.08	0.08	0.09
R	Essential thrombocythemia	3,886	0.48	0.46	0.49	2,557	4.00	3.84	4.15	3,886	0.48	0.46	0.49

R	Polycythemia vera	5,353	0.66	0.64	0.68	3,173	4.96	4.79	5.13	5,353	0.66	0.64	0.68
R	Mast cell tumours	125	0.02	0.01	0.02	55	0.09	0.07	0.11	86	0.01	0.01	0.01
R	Myeloproliferative diseases other	4,284	0.53	0.51	0.54	1,982	3.10	2.96	3.24	3,048	0.38	0.36	0.38
R	MYELODISPLASTIC SYNDROME	12,082	1.49	1.46	1.52	2,521	3.94	3.79	4.10	9,447	1.17	1.14	1.19
	MYELODISPLASTIC MYELOPROLIFERATIVE DISEASES	2,328	0.29	0.28	0.3	414	0.65	0.59	0.71	2,328	0.29	0.28	0.30
R	Chronic myelomonocytic leukemia NOS	2,319	0.29	0.27	0.3	411	0.64	0.58	0.71	2,319	0.29	0.27	0.30
R	Juvenile myelomonocytic leukemia	3	0.00	0.00	0.00	1	0.00	0.00	0.01	3	0.00	0.00	0.00
R	Atypical chronic myeloid leukemia BCRABL negative	6	0.00	0.00	0.00	2	0.00	0.00	0.01	6	0.00	0.00	0.00
R	HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS	394	0.05	0.04	0.05	311	0.49	0.43	0.54	204	0.03	0.02	0.03

* ICD-O3 code not available

F = frequent tumour entity; R = rare tumour entity; NE = not estimated

Table 6. Crude annual incidence and mortality rate and prevalence proportion by layer 1 tumour entity. Rates and proportions are per 100,000.

Tumour entities	Incidence				Prevalence				Mortality			
	N. of cases	Crude rate	Lower	Upper	N. of cases	Crude rate	Lower	Upper	N. of cases	Crude rate	Lower	Upper
RARE												
EPITHELIAL TUMOURS OF THE NASAL CAVITY AND SINUSES	3,594	0.44	0.43	0.46	1,453	2.27	2.15	2.39	2,221	0.27	0.27	0.28
EPITHELIAL TUMOURS OF THE NASOPHARYNX	3,618	0.45	0.43	0.46	1,398	2.18	2.07	2.30	2,385	0.30	0.28	0.30
EPITHELIAL TUMOURS OF MAJOR SALIVARY GLANDS AND SALIVARY GLAND TYPE TUMORS	10,633	1.31	1.29	1.34	5,570	8.70	8.48	8.93	4,906	0.60	0.60	0.62
EPITHELIAL TUMOURS OF THE OROPHARYNX	22,337	2.75	2.72	2.79	7,330	11.45	11.19	11.72	19,412	2.39	2.36	2.42
EPITHELIAL TUMOURS OF THE ORAL CAVITY AND LIP	38,892	4.8	4.75	4.84	16,846	26.32	25.93	26.72	NE	NE	NE	NE
EPITHELIAL TUMOURS OF THE SMALL INTESTINE	5,882	0.73	0.71	0.74	1,305	2.04	1.93	2.15	4,691	0.58	0.57	0.59
EPITHELIAL TUMOURS OF THE ANAL CANAL	8,922	1.10	1.08	1.12	4,133	6.46	6.26	6.66	5,653	0.70	0.68	0.71
EPITHELIAL TUMOURS GALLBLADDER AND EXTRAHEPATIC BILIARY DUCT	35,840	4.42	4.37	4.47	3,940	6.16	5.96	6.35	33,298	4.11	4.06	4.15
EPITHELIAL TUMOURS OF THE TRACHEA	1,090	0.13	0.13	0.14	155	0.24	0.21	0.28	1,044	0.12	0.12	0.13
EPITHELIAL TUMOURS OF THE THYMUS	1,364	0.17	0.16	0.18	623	0.97	0.90	1.05	1,188	0.15	0.14	0.16
MIXED EPITHELIAL AND MESENCHYMAL TUMOURS OF THE UTERUS	3,613	0.45	0.43	0.46	1,304	2.04	1.93	2.15	2,597	0.32	0.31	0.33
NON EPITHELIAL TUMOURS OF THE OVARY	3,513	0.43	0.42	0.45	2,074	3.24	3.10	3.38	NE	NE	NE	NE
EPITHELIAL TUMOURS OF THE VULVA & VAGINA	15,522	1.91	1.88	1.94	7,374	11.52	11.26	11.79	8,049	0.99	0.97	1.01
TROPHOBLASTIC TUMOURS OF THE PLACENTA	192	0.02	0.02	0.03	236	0.37	0.32	0.42	19	0.00	0.00	0.00

TUMOURS OF THE TESTIS AND PARATESTIS	25,510	3.15	3.11	3.18	26,722	41.75	41.25	42.26	3,154	0.39	0.38	0.39
EPITHELIAL TUMOURS OF THE PENIS	5,058	0.62	0.61	0.64	2,635	4.12	3.96	4.28	1,877	0.23	0.23	0.24
EPITHELIAL TUMOURS OF THE PELVIS URETHRA AND URETHRA	12,888	1.59	1.56	1.62	5,569	8.70	8.47	8.93	7,723	0.95	0.93	0.97
EPITHELIAL TUMOURS OF THE EYE AND ADNEXA	1,286	0.16	0.15	0.17	750	1.17	1.09	1.26	497	0.06	0.06	0.07
EPITHELIAL TUMOURS OF THE MIDDLE EAR	245	0.03	0.03	0.03	103	0.16	0.13	0.19	161	0.02	0.02	0.02
MALIGNANT MESOTHELIOMA	15,456	1.91	1.88	1.94	1,427	2.23	2.12	2.35	15,186	1.88	1.85	1.91
MALIGNANT MELANOMA OF THE MUCOSA	4,132	0.51	0.49	0.53	1,059	1.66	1.56	1.76	3,250	0.40	0.39	0.42
MALIGNANT MELANOMA OF THE UVEA	5,301	0.65	0.64	0.67	3,306	5.17	4.99	5.35	2,242	0.27	0.27	0.28
ADNEXAL CARCINOMA OF THE SKIN	2,247	0.28	0.27	0.29	1,312	2.05	1.94	2.16	2,247	0.28	0.27	0.29
EMBRYONAL NEOPLASMS	2,789	0.34	0.33	0.36	2,399	3.75	3.60	3.90	1,073	0.13	0.13	0.14
EXTRAGONADIC GERM CELL TUMOURS	1,028	0.13	0.12	0.13	687	1.07	0.99	1.16	396	0.05	0.05	0.05
SOFT TISSUE SARCOMA	38,527	4.75	4.7	4.8	18,335	28.65	28.23	29.07	23,756	2.93	2.90	2.96
BONE SARCOMA	6,523	0.8	0.79	0.82	3,735	5.84	5.65	6.03	4,539	0.56	0.55	0.57
GASTROINTESTINAL STROMAL SARCOMA	536	0.07	0.06	0.07	224	0.35	0.31	0.40	305	0.04	0.03	0.04
KAPOSI SARCOMA	2,925	0.36	0.35	0.37	980	1.53	1.44	1.63	2,637	0.32	0.32	0.33
NEURO ENDOCRINE TUMOURS	20,466	2.52	2.49	2.56	8,465	13.23	12.95	13.51	15,390	1.89	1.87	1.93
CARCINOMA OF ENDOCRINE ORGANS	33,757	4.16	4.12	4.21	23,316	36.43	35.96	36.90	NE	NE	NE	NE
GLIAL TUMOURS OF THE CENTRAL NERVOUS SYSTEM AND PINEAL GLAND	43,344	5.35	5.29	5.4	9,286	14.51	14.21	14.81	41,208	5.09	5.03	5.13
NON GLIAL TUMOURS OF THE CENTRAL NERVOUS SYSTEM AND PINEAL GLAND	1,816	0.22	0.21	0.23	1,028	1.61	1.51	1.71	1,077	0.13	0.12	0.14
MALIGNANT MENINGIOMAS	1,225	0.15	0.14	0.16	769	1.20	1.12	1.29	826	0.10	0.09	0.11

GLIAL TUMOURS OF THE OF THE NERVES, AUTONOMIC NERVOUS SYSTEM AND PARAGANGLIA	82	0.01	0.01	0.01	60	0.09	0.07	0.12	18	0.00	0.00	0.00
NON-GLIAL TUMOURS OF THE OF THE NERVES, AUTONOMIC NERVOUS SYSTEM AND PARAGANGLIA	800	0.10	0.09	0.11	467	0.73	0.66	0.80	521	0.07	0.06	0.07
ACUTE MYELOID LEUKAEMIA AND RELATED PRECURSOR NEOPLASMS	29,982	3.70	3.66	3.74	4,953	7.74	7.53	7.96	28,686	3.54	3.50	3.58
MYELOPROLIFERATIVE NEOPLASMS	24,859	3.07	3.03	3.1	11,189	17.48	17.16	17.81	23,771	2.94	2.90	2.96
MYELODISPLASTIC SYNDROME	12,082	1.49	1.46	1.52	2,521	3.94	3.79	4.10	9,447	1.17	1.14	1.19
MYELODISPLASTIC MYELOPROLIFERATIVE DISEASES	2,328	0.29	0.28	0.3	414	0.65	0.59	0.71	2,328	0.29	0.28	0.30
HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS	394	0.05	0.04	0.05	311	0.49	0.43	0.54	204	0.03	0.02	0.03
FREQUENT												
EPITHELIAL TUMOURS OF THE HYPOPHARYNX AND LARYNX	51,000	6.29	6.23	6.34	19,578	30.59	30.16	31.02	30,666	3.78	3.75	3.81
EPITHELIAL TUMOURS OF THE OESOPHAGUS	60,723	7.49	7.43	7.55	7,109	11.11	10.85	11.37	57,804	7.13	7.07	7.19
EPITHELIAL TUMOURS OF THE STOMACH	151,346	18.66	18.57	18.76	26,764	41.82	41.32	42.32	128,769	15.88	15.80	15.96
EPITHELIAL TUMOURS OF THE COLON	346,910	42.78	42.64	42.92	133,758	208.99	207.88	210.12	214,957	26.51	26.42	26.59
EPITHELIAL TUMOURS OF THE RECTUM	138,806	17.12	17.03	17.21	60,099	93.90	93.15	94.66	95,392	11.77	11.70	11.83
EPITHELIAL TUMOURS OF THE PANCREAS	95,836	11.82	11.74	11.89	4,936	7.71	7.50	7.93	93,658	11.55	11.47	11.62
EPITHELIAL TUMOURS LIVER AND INTRAHEPATIC BILE TRACT IBT	50,933	6.28	6.23	6.34	3,493	5.46	5.28	5.64	50,560	6.23	6.18	6.29
EPITHELIAL TUMOURS OF THE LUNG	454,883	56.10	55.93	56.26	49,225	76.91	76.23	77.59	432,572	53.35	53.19	53.50
EPITHELIAL TUMOURS OF THE BREAST	519,188	64.03	63.85	64.20	339,598	530.61	528.83	532.40	247,603	30.54	30.45	30.62
EPITHELIAL TUMOURS OF THE CORPUS UTERI	84,500	10.42	10.35	10.49	59,973	93.71	92.96	94.46	28,647	3.53	3.51	3.56
EPITHELIAL TUMOURS OF THE CERVIX UTERI	49,259	6.07	6.02	6.13	37,713	58.93	58.33	59.52	20,984	2.59	2.56	2.61
EPITHELIAL TUMOURS OF THE OVARY AND FALLOPIAN TUBE	76,284	9.41	9.34	9.47	28,525	44.57	44.05	45.09	61,632	7.60	7.55	7.65
EPITHELIAL TUMOURS OF THE	388,741	47.94	47.79	48.09	185,701	290.15	288.84	291.48	321,397	39.64	39.51	39.76

PROSTATE												
EPITHELIAL TUMOURS OF THE KIDNEY	85,671	10.56	10.49	10.64	37,169	58.08	57.49	58.67	63,861	7.87	7.82	7.93
EPITHELIAL TUMOURS OF THE BLADDER	163,624	20.18	20.08	20.28	74,279	116.06	115.23	116.90	77,406	9.55	9.50	9.59
MALIGNANT SKIN MELANOMA	100,883	12.44	12.36	12.52	79,245	123.82	122.96	124.68	31,572	3.89	3.87	3.92
EPITHELIAL TUMOURS OF THE SKIN	397,503	49.02	48.87	49.17	257,623	402.53	400.98	404.09	NE	NE	NE	NE
LYMPHOID DISEASES	236,546	29.17	29.05	29.29	99,405	155.32	154.35	156.29	226,766	27.96	27.85	28.08

Table 7. One- and 5-year relative survival by tumour entities for the period 1995-99 (cohort survival analysis) and 2000-2002 (period survival analysis)

Tumour entities		years since diagn.	Number of cases	Cohort (1995-99)			Period (2000-2002)		
				Survival (%)	Lower 95%CI	Upper 95%CI	Survival (%)	Lower 95%CI	Upper 95%CI
	EPITHELIAL TUMOURS OF THE NASAL CAVITY AND SINUSES	1 yr	2,391	74.30	72.36	76.13	74.76	71.76	77.49
	EPITHELIAL TUMOURS OF THE NASAL CAVITY AND SINUSES	5 yr	2,391	47.91	45.46	50.32	49.00	45.40	52.50
R	Squamous cell carcinoma and variants of the Nasal Cavity and Sinuses	1 yr	1,680	76.68	74.41	78.78	77.50	74.09	80.52
R	Squamous cell carcinoma and variants of the Nasal Cavity and Sinuses	5 yr	1,680	48.99	46.06	51.86	50.70	46.44	54.79
R	Lymphoepithelial carcinoma of the Nasal Cavity and Sinuses	1 yr	15	81.10	49.61	93.93	25.78	0.87	67.88
R	Lymphoepithelial carcinoma of the Nasal Cavity and Sinuses	5 yr	15	28.81	8.69	53.05	4.53	0.06	27.61
R	Undifferentiated carcinoma of the Nasal Cavity and Sinuses	1 yr	82	56.59	44.77	66.81	64.91	50.59	76.03
R	Undifferentiated carcinoma of the Nasal Cavity and Sinuses	5 yr	82	32.53	21.50	44.03	38.93	23.48	54.11
R	Intestinal type adenocarcinoma the Nasal Cavity and Sinuses	1 yr	16	96.42	31.08	99.89	77.34	9.79	97.20
R	Intestinal type adenocarcinoma the Nasal Cavity and Sinuses	5 yr	16	50.09	20.63	73.88	23.48	3.43	53.67
	EPITHELIAL TUMOURS OF THE NASOPHARYNX	1 yr	2,503	76.04	74.25	77.73	77.97	75.06	80.58
	EPITHELIAL TUMOURS OF THE NASOPHARYNX	5 yr	2,503	49.16	46.94	51.33	49.85	46.39	53.21
R	Squamous cell carcinoma and variants of the Nasopharynx	1 yr	1,844	77.46	75.40	79.38	79.11	75.89	81.95
R	Squamous cell carcinoma and variants of the Nasopharynx	5 yr	1,844	49.14	46.57	51.67	50.21	46.28	54.01
R	Papillary adenocarcinoma of the Nasopharynx	1 yr	5	80.43	19.61	97.13	100.55	—	—
R	Papillary adenocarcinoma of the Nasopharynx	5 yr	5	58.76	9.36	88.75	NE	NE	NE
	EPITHELIAL TUMOURS OF THE MAJOR SALIVARY GLANDS AND SALIVARY GLAND TYPE TUMORS	1 yr	7,087	83.39	82.41	84.32	84.02	82.54	85.37
	EPITHELIAL TUMOURS OF THE MAJOR SALIVARY GLANDS AND SALIVARY GLAND TYPE TUMORS	5 yr	7,087	64.80	63.37	66.18	65.49	63.43	67.47
R	Epithelial tumours of the major salivary glands	1 yr	3,934	83.76	82.44	85.00	85.43	83.53	87.13
R	Epithelial tumours of the major salivary glands	5 yr	3,934	64.55	62.62	66.42	65.58	62.82	68.18
R	Salivary gland type tumours of the Head and Neck	1 yr	2,398	87.22	85.67	88.62	86.92	84.43	89.04
R	Salivary gland type tumours of the Head and Neck	5 yr	2,398	69.14	66.80	71.35	70.79	67.29	73.99
	EPITHELIAL TUMOURS OF THE HYPOPHARYNX AND LARYNX	1 yr	35,582	80.02	79.57	80.46	79.97	79.25	80.68
	EPITHELIAL TUMOURS OF THE HYPOPHARYNX AND LARYNX	5 yr	35,582	54.99	54.37	55.60	55.38	54.44	56.30
R	Squamous cell carcinoma and variants of the Hypopharynx	1 yr	6,924	61.94	60.75	63.11	60.31	58.34	62.23
R	Squamous cell carcinoma and variants of the Hypopharynx	5 yr	6,924	24.55	23.44	25.68	24.32	22.61	26.07

R	Squamous cell carcinoma and variants of the Larynx	1 yr	26,672	86.21	85.75	86.66	86.24	85.50	86.94
R	Squamous cell carcinoma and variants of the Larynx	5 yr	26,672	63.92	63.20	64.62	63.88	62.81	64.94
	EPITHELIAL TUMOURS OF THE OROPHARYNX	1 yr	14,912	68.77	67.99	69.53	70.67	69.53	71.77
	EPITHELIAL TUMOURS OF THE OROPHARYNX	5 yr	14,912	37.03	36.18	37.89	39.90	38.62	41.18
R	Squamous cell carcinoma and variants of the Oropharynx	1 yr	14,205	69.56	68.77	70.33	71.26	70.10	72.38
R	Squamous cell carcinoma and variants of the Oropharynx	5 yr	14,205	37.16	36.28	38.04	40.00	38.69	41.30
	EPITHELIAL TUMOURS OF THE ORAL CAVITY AND LIP	1 yr	26,710	81.20	80.68	81.71	80.52	79.70	81.31
	EPITHELIAL TUMOURS OF THE ORAL CAVITY AND LIP	5 yr	26,710	59.17	58.43	59.89	57.77	56.68	58.85
R	Squamous cell carcinoma and variants of the Oral cavity	1 yr	18,353	75.75	75.08	76.40	75.17	74.14	76.16
R	Squamous cell carcinoma and variants of the Oral cavity	5 yr	18,353	48.29	47.44	49.13	47.65	46.41	48.88
R	Squamous cell carcinoma and variants of the Lip	1 yr	7,024	98.11	97.37	98.63	98.20	96.84	98.97
R	Squamous cell carcinoma and variants of the Lip	5 yr	7,024	91.66	90.12	92.97	90.67	88.21	92.64
	EPITHELIAL TUMOURS OF THE OESOPHAGUS	1 yr	39,951	33.23	32.75	33.71	36.67	35.93	37.41
	EPITHELIAL TUMOURS OF THE OESOPHAGUS	5 yr	39,951	10.65	10.31	11.01	11.56	11.01	12.13
R	Squamous cell carcinoma and variants of the Oesophagus	1 yr	19,263	34.65	33.96	35.34	36.32	35.22	37.42
R	Squamous cell carcinoma and variants of the Oesophagus	5 yr	19,263	10.67	10.18	11.17	11.26	10.49	12.06
R	Adenocarcinoma and variants of the Oesophagus	1 yr	14,659	36.95	36.14	37.77	41.04	39.89	42.18
R	Adenocarcinoma and variants of the Oesophagus	5 yr	14,659	11.74	11.14	12.36	13.07	12.15	14.02
R	Salivary gland type tumours of the Oesophagus	1 yr	37	36.24	20.96	51.72	47.02	13.98	74.87
R	Salivary gland type tumours of the Oesophagus	5 yr	37	9.56	2.41	22.78	6.10	0.32	25.60
R	Undifferentiated carcinoma of the Oesophagus	1 yr	430	20.15	16.40	24.19	23.43	16.90	30.60
R	Undifferentiated carcinoma of the Oesophagus	5 yr	430	7.28	4.77	10.48	6.14	2.86	11.18
	EPITHELIAL TUMOURS OF THE STOMACH	1 yr	101,446	41.79	41.47	42.10	43.38	42.88	43.89
	EPITHELIAL TUMOURS OF THE STOMACH	5 yr	101,446	21.70	21.40	22.00	22.27	21.80	22.73
F	Adenocarcinoma and variants of the Stomach	1 yr	86,014	45.15	44.81	45.50	46.33	45.78	46.87
F	Adenocarcinoma and variants of the Stomach	5 yr	86,014	23.16	22.82	23.49	23.54	23.04	24.05
R	Squamous cell carcinoma and variants of the Stomach	1 yr	713	31.71	28.22	35.26	34.42	28.84	40.06
R	Squamous cell carcinoma and variants of the Stomach	5 yr	713	14.14	11.35	17.23	16.31	11.83	21.42
R	Salivary gland type tumours of the Stomach	1 yr	35	44.36	27.21	60.18	35.04	4.57	70.01
R	Salivary gland type tumours of the Stomach	5 yr	35	20.57	8.02	37.13	14.71	0.48	50.18
R	Undifferentiated carcinoma of the Stomach	1 yr	968	26.30	23.47	29.20	27.12	22.71	31.71
R	Undifferentiated carcinoma of the Stomach	5 yr	968	13.13	10.77	15.73	12.62	9.35	16.41
	EPITHELIAL TUMOURS OF THE SMALL INTESTINE	1 yr	3,730	46.97	45.30	48.62	51.13	48.64	53.56
	EPITHELIAL TUMOURS OF THE SMALL INTESTINE	5 yr	3,730	25.35	23.74	26.98	28.00	25.55	30.50
R	Adenocarcinoma and variants of the Small Intestine	1 yr	3,026	49.48	47.62	51.31	53.58	50.85	56.23
R	Adenocarcinoma and variants of the Small Intestine	5 yr	3,026	25.70	23.93	27.51	27.77	25.12	30.47
R	Squamous cell carcinoma and variants of the Small Intestine	1 yr	34	33.39	18.11	49.44	70.58	37.31	88.41
R	Squamous cell carcinoma and variants of the Small Intestine	5 yr	34	20.72	8.24	37.08	79.07	33.32	95.11

	EPITHELIAL TUMOURS OF THE COLON	1 yr	228,575	72.77	72.57	72.96	74.62	74.33	74.90
	EPITHELIAL TUMOURS OF THE COLON	5 yr	228,575	53.23	52.97	53.49	55.27	54.88	55.66
F	Adenocarcinoma and variants of the Colon	1 yr	203,768	77.51	77.31	77.70	78.65	78.36	78.93
F	Adenocarcinoma and variants of the Colon	5 yr	203,768	56.38	56.10	56.65	57.96	57.56	58.36
R	Squamous cell carcinoma and variants of the Colon	1 yr	119	43.95	34.55	52.94	54.46	37.92	68.33
R	Squamous cell carcinoma and variants of the Colon	5 yr	119	31.73	22.03	41.85	41.44	23.50	58.52
	EPITHELIAL TUMOURS OF THE RECTUM	1 yr	92,063	77.14	76.84	77.44	79.06	78.63	79.49
	EPITHELIAL TUMOURS OF THE RECTUM	5 yr	92,063	52.59	52.18	53.00	54.83	54.23	55.42
F	Adenocarcinoma and variants of the Rectum	1 yr	84,604	79.85	79.55	80.15	81.29	80.86	81.72
F	Adenocarcinoma and variants of the Rectum	5 yr	84,604	54.37	53.94	54.79	56.36	55.74	56.97
R	Squamous cell carcinoma and variants of the Rectum	1 yr	411	71.16	66.21	75.52	77.04	69.83	82.74
R	Squamous cell carcinoma and variants of the Rectum	5 yr	411	50.18	44.20	55.87	53.24	44.35	61.34
R	Basaloid carcinoma of the Rectum	1 yr	88	74.17	62.87	82.50	64.58	43.25	79.61
R	Basaloid carcinoma of the Rectum	5 yr	88	51.08	37.80	62.88	50.73	29.42	68.63
	EPITHELIAL TUMOURS OF THE ANAL CANAL	1 yr	5,993	80.53	79.40	81.60	81.61	79.92	83.18
	EPITHELIAL TUMOURS OF THE ANAL CANAL	5 yr	5,993	55.53	53.94	57.08	57.99	55.65	60.24
R	Squamous cell carcinoma and variants of the Anal Canal	1 yr	3,357	85.16	83.77	86.43	85.38	83.36	87.18
R	Squamous cell carcinoma and variants of the Anal Canal	5 yr	3,357	61.45	59.38	63.45	63.54	60.56	66.36
R	Adenocarcinoma and variants of the Anal Canal	1 yr	1,425	75.82	73.27	78.17	77.70	73.71	81.16
R	Adenocarcinoma and variants of the Anal Canal	5 yr	1,425	42.41	39.18	45.60	46.09	41.12	50.91
R	Basaloid carcinoma of the Anal Canal	1 yr	686	86.48	83.32	89.08	85.64	80.32	89.61
R	Basaloid carcinoma of the Anal Canal	5 yr	686	61.09	56.35	65.47	59.35	52.40	65.63
R	Paget disease of the Anal Canal	1 yr	23	67.91	43.31	83.62	106.04	—	—
R	Paget disease of the Anal Canal	5 yr	23	59.88	30.76	80.00	104.37	—	—
	EPITHELIAL TUMOURS OF THE PANCREAS	1 yr	57,468	16.45	16.14	16.76	17.64	17.17	18.11
	EPITHELIAL TUMOURS OF THE PANCREAS	5 yr	57,468	3.76	3.58	3.94	3.79	3.54	4.05
F	Adenocarcinoma and variants of the Pancreas	1 yr	38,658	17.29	16.91	17.68	19.76	19.16	20.36
F	Adenocarcinoma and variants of the Pancreas	5 yr	38,658	3.39	3.19	3.60	3.76	3.46	4.08
R	Squamous cell carcinoma and variants of the Pancreas	1 yr	130	18.04	11.85	25.27	9.24	3.80	17.65
R	Squamous cell carcinoma and variants of the Pancreas	5 yr	130	9.63	4.91	16.26	6.20	1.89	14.25
R	Acinar cell carcinoma of the Pancreas	1 yr	112	36.73	27.70	45.77	24.33	13.48	36.89
R	Acinar cell carcinoma of the Pancreas	5 yr	112	21.35	13.60	30.27	19.85	9.68	32.63
R	Mucinous cystadenocarcinoma of the Pancreas	1 yr	36	68.12	49.63	81.03	56.24	33.76	73.71
R	Mucinous cystadenocarcinoma of the Pancreas	5 yr	36	36.53	19.89	53.37	28.84	11.77	48.55
R	Intraductal papillary mucinous carcinoma invasive of the Pancreas	1 yr	0	NE	NE	NE	103.47	—	—
R	Intraductal papillary mucinous carcinoma invasive of the Pancreas	5 yr	0	NE	NE	NE	NE	NE	NE
R	Solid pseudopapillary carcinoma of the Pancreas	1 yr	3	101.08	—	—	100.86	—	—
R	Solid pseudopapillary carcinoma of the Pancreas	5 yr	3	70.68	3.07	96.60	NE	NE	NE

R	Serous cystadenocarcinoma of the Pancreas	1 yr	1	100.42	—	—	NE	NE	NE
R	Serous cystadenocarcinoma of the Pancreas	5 yr	1	102.22	—	—	NE	NE	NE
R	Carcinoma with osteoclast-like giant cells of the Pancreas	1 yr	0	NE	NE	NE	NE	NE	NE
R	Carcinoma with osteoclast-like giant cells of the Pancreas	5 yr	0	NE	NE	NE	NE	NE	NE
	EPITHELIAL TUMOURS LIVER AND INTRAHEPATIC BILE TRACT (IBT)	1 yr	31,083	30.30	29.78	30.83	32.34	31.55	33.13
	EPITHELIAL TUMOURS LIVER AND INTRAHEPATIC BILE TRACT (IBT)	5 yr	31,083	8.81	8.45	9.18	9.86	9.32	10.42
R	Hepatocellular carcinoma of the Liver and IBT	1 yr	16,329	36.99	36.23	37.75	39.30	38.14	40.46
R	Hepatocellular carcinoma of the Liver and IBT	5 yr	16,329	11.72	11.16	12.28	13.35	12.50	14.22
R	Cholangiocarcinoma of the IBT	1 yr	4,006	22.49	21.18	23.84	22.51	20.69	24.37
R	Cholangiocarcinoma of the IBT	5 yr	4,006	5.52	4.74	6.38	5.53	4.46	6.75
R	Adenocarcinoma and variants of the Liver and IBT	1 yr	1,039	22.29	19.75	24.92	23.65	20.10	27.38
R	Adenocarcinoma and variants of the Liver and IBT	5 yr	1,039	5.37	3.97	7.06	4.59	2.98	6.71
R	Undifferentiated carcinoma of the Liver and IBT	1 yr	67	10.81	4.74	19.72	3.06	0.23	13.49
R	Undifferentiated carcinoma of the Liver and IBT	5 yr	67	3.62	0.67	11.07	NE	NE	NE
R	Squamous cell carcinoma and variants of the Liver and IBT	1 yr	52	24.03	13.27	36.54	27.45	13.62	43.26
R	Squamous cell carcinoma and variants of the Liver and IBT	5 yr	52	9.56	3.00	20.77	NE	NE	NE
R	Bile duct cystadenocarcinoma of the IBT	1 yr	9	45.05	13.63	72.68	75.83	11.78	96.49
R	Bile duct cystadenocarcinoma of the IBT	5 yr	9	12.13	0.63	41.55	NE	NE	NE
	EPITHELIAL TUMOURS GALLBLADDER AND EXTRAHEPATIC BILIARY DUCT (EBT)	1 yr	22,905	31.07	30.45	31.69	32.36	31.39	33.34
	EPITHELIAL TUMOURS GALLBLADDER AND EXTRAHEPATIC BILIARY DUCT (EBT)	5 yr	22,905	12.65	12.15	13.16	13.04	12.29	13.81
R	Adenocarcinoma and variants of the Gallbladder and EBT	1 yr	14,328	37.49	36.68	38.31	39.43	38.17	40.69
R	Adenocarcinoma and variants of the Gallbladder and EBT	5 yr	14,328	15.11	14.44	15.79	15.92	14.93	16.95
R	Combined hepatocellular carcinoma and cholangiocarcinoma of the Gallbladder and EBT	1 yr	3	34.40	0.84	78.80	0.00	—	—
R	Combined hepatocellular carcinoma and cholangiocarcinoma of the Gallbladder and EBT	5 yr	3	39.18	0.57	84.38	NE	NE	NE
R	Squamous cell carcinoma of the Gallbladder and EBT	1 yr	198	17.68	12.62	23.46	15.46	8.40	24.48
R	Squamous cell carcinoma of the Gallbladder and EBT	5 yr	198	12.20	7.61	17.93	9.61	4.24	17.63
	EPITHELIAL TUMOURS OF THE TRACHEA	1 yr	742	32.25	28.83	35.71	38.10	32.36	43.81
	EPITHELIAL TUMOURS OF THE TRACHEA	5 yr	742	12.16	9.68	14.94	14.16	9.98	19.05
R	Squamous cell carcinoma and variants of the Trachea	1 yr	473	29.59	25.45	33.84	33.35	26.19	40.66
R	Squamous cell carcinoma and variants of the Trachea	5 yr	473	8.49	5.95	11.57	9.47	5.25	15.18
R	Adenocarcinoma and variants of the Trachea	1 yr	76	33.74	23.22	44.55	36.29	19.81	53.02
R	Adenocarcinoma and variants of the Trachea	5 yr	76	7.56	2.77	15.57	5.89	1.15	16.57
R	Salivary gland type tumours of the Trachea	1 yr	53	84.23	70.55	91.90	97.02	66.83	99.77
R	Salivary gland type tumours of the Trachea	5 yr	53	56.18	40.21	69.42	57.93	32.16	76.90
	EPITHELIAL TUMOURS OF THE LUNG	1 yr	290,236	32.56	32.39	32.74	33.98	33.72	34.25

	EPITHELIAL TUMOURS OF THE LUNG	5 yr	290,236	10.60	10.47	10.72	10.99	10.80	11.17
F	Squamous cell carcinoma and variants of the Lung	1 yr	76,491	40.17	39.81	40.53	41.68	41.10	42.26
F	Squamous cell carcinoma and variants of the Lung	5 yr	76,491	13.43	13.16	13.71	13.62	13.21	14.04
F	Adenocarcinoma and variants of the Lung	1 yr	53,989	39.44	39.02	39.86	41.71	41.10	42.31
F	Adenocarcinoma and variants of the Lung	5 yr	53,989	13.91	13.59	14.24	14.64	14.18	15.10
R	Large cell carcinoma of the Lung	1 yr	22,798	35.20	34.56	35.83	36.84	35.82	37.86
R	Large cell carcinoma of the Lung	5 yr	22,798	12.35	11.87	12.83	13.24	12.51	13.99
R	Well differentiated endocrine carcinoma of the lung	1 yr	3,208	74.10	72.49	75.64	69.64	67.36	71.79
R	Well differentiated endocrine carcinoma of the lung	5 yr	3,208	58.86	56.90	60.76	55.30	52.67	57.85
F	Poorly differentiated endocrine carcinoma of the Lung	1 yr	41,616	28.13	27.69	28.57	28.86	28.19	29.52
F	Poorly differentiated endocrine carcinoma of the Lung	5 yr	41,616	4.56	4.34	4.78	4.87	4.55	5.21
R	Bronchiolo-alveolar carcinoma of the Lung	1 yr	3,639	57.84	56.16	59.48	62.97	60.49	65.34
R	Bronchiolo-alveolar carcinoma of the Lung	5 yr	3,639	31.31	29.60	33.03	34.38	31.87	36.91
R	Salivary gland type tumours of the Lung	1 yr	240	62.20	55.54	68.15	65.56	55.53	73.86
R	Salivary gland type tumours of the Lung	5 yr	240	43.17	36.09	50.03	39.80	29.45	49.94
R	Sarcomatoid carcinoma of the Lung	1 yr	735	33.81	30.33	37.32	37.17	31.94	42.40
R	Sarcomatoid carcinoma of the Lung	5 yr	735	15.90	13.09	18.96	17.96	13.46	23.00
R	Undifferentiated carcinoma of the Lung	1 yr	5,388	26.60	25.40	27.81	28.57	26.74	30.43
R	Undifferentiated carcinoma of the Lung	5 yr	5,388	6.65	5.94	7.41	7.99	6.85	9.23
	EPITHELIAL TUMOURS OF THE THYMUS	1 yr	903	79.47	76.56	82.06	84.36	80.20	87.72
	EPITHELIAL TUMOURS OF THE THYMUS	5 yr	903	57.40	53.68	60.94	64.56	59.05	69.53
R	Malignant tymoma	1 yr	750	82.34	79.28	84.99	87.23	82.88	90.53
R	Malignant tymoma	5 yr	750	60.60	56.53	64.42	68.36	62.40	73.58
R	Squamous cell carcinoma of the Thymus	1 yr	25	69.48	46.67	84.03	71.86	32.36	90.77
R	Squamous cell carcinoma of the Thymus	5 yr	25	44.63	23.16	64.08	57.78	19.38	83.25
R	Undifferentiated carcinoma of the Thymus	1 yr	12	59.27	27.12	81.09	43.79	9.76	74.59
R	Undifferentiated carcinoma of the Thymus	5 yr	12	18.21	2.79	44.47	NE	NE	NE
R	Lymphoepithelial carcinoma of the Thymus	1 yr	3	100.25	—	—	67.21	5.09	94.84
R	Lymphoepithelial carcinoma of the Thymus	5 yr	3	67.64	4.85	95.07	NE	NE	NE
R	Adenocarcinoma and variants of the Thymus	1 yr	11	62.51	27.53	84.27	61.76	11.91	89.66
R	Adenocarcinoma and variants of the Thymus	5 yr	11	32.75	7.66	61.56	NE	NE	NE
	EPITHELIAL TUMOURS OF THE BREAST	1 yr	343,750	94.41	94.32	94.50	95.67	95.54	95.79
	EPITHELIAL TUMOURS OF THE BREAST	5 yr	343,750	80.63	80.46	80.80	82.62	82.38	82.87
F	Invasive ductal carcinoma of the Breast	1 yr	216,514	97.48	97.39	97.56	97.60	97.47	97.71
F	Invasive ductal carcinoma of the Breast	5 yr	216,514	83.55	83.34	83.75	84.48	84.20	84.76
F	Invasive lobular carcinoma of the Breast	1 yr	38,072	97.62	97.41	97.82	97.54	97.23	97.82
F	Invasive lobular carcinoma of the Breast	5 yr	38,072	86.01	85.53	86.48	86.19	85.51	86.84
R	Mammary Paget's disease of the Breast	1 yr	2,880	97.64	96.66	98.34	98.03	96.23	98.97

R	Mammary Paget's disease of the Breast	5 yr	2,880	83.04	80.98	84.90	83.87	80.65	86.60
R	Special types of adenocarcinoma of the Breast	1 yr	19,573	98.86	98.57	99.09	99.28	98.81	99.56
R	Special types of adenocarcinoma of the Breast	5 yr	19,573	95.36	94.74	95.91	95.91	95.00	96.66
R	Metaplastic carcinoma of the Breast	1 yr	304	86.73	81.89	90.35	88.39	82.34	92.46
R	Metaplastic carcinoma of the Breast	5 yr	304	66.15	59.19	72.21	66.53	57.14	74.32
R	Salivary gland type tumours of the Breast	1 yr	314	97.28	93.62	98.85	101.35	—	—
R	Salivary gland type tumours of the Breast	5 yr	314	85.36	79.24	89.80	89.23	77.86	94.95
R	Epithelial tumours of the Male Breast	1 yr	2,537	91.38	89.91	92.65	91.50	89.23	93.31
R	Epithelial tumours of the Male Breast	5 yr	2,537	77.45	74.86	79.82	74.29	70.51	77.67
	EPITHELIAL TUMOURS OF THE CORPUS UTERI	1 yr	54,701	90.69	90.41	90.96	91.83	91.44	92.20
	EPITHELIAL TUMOURS OF THE CORPUS UTERI	5 yr	54,701	79.45	79.00	79.89	80.82	80.18	81.44
F	Adenocarcinoma and variants of the Corpus Uteri	1 yr	50,703	92.85	92.58	93.10	93.71	93.35	94.05
F	Adenocarcinoma and variants of the Corpus Uteri	5 yr	50,703	81.31	80.86	81.76	82.46	81.82	83.08
R	Squamous cell carcinoma and variants of the Corpus Uteri	1 yr	652	67.55	63.65	71.13	71.01	64.68	76.42
R	Squamous cell carcinoma and variants of the Corpus Uteri	5 yr	652	53.35	48.79	57.70	54.84	47.75	61.37
R	Adenoid cystic carcinoma of the Corpus Uteri	1 yr	10	70.77	32.69	89.86	101.71	—	—
R	Adenoid cystic carcinoma of the Corpus Uteri	5 yr	10	74.52	31.08	92.87	NE	NE	NE
R	Transitional cell carcinoma of the Corpus Uteri	1 yr	0	NE	NE	NE	102.63	—	—
R	Transitional cell carcinoma of the Corpus Uteri	5 yr	0	NE	NE	NE	NE	NE	NE
	EPITHELIAL TUMOURS OF THE CERVIX UTERI	1 yr	33,735	85.56	85.16	85.95	86.11	85.49	86.70
	EPITHELIAL TUMOURS OF THE CERVIX UTERI	5 yr	33,735	66.62	66.05	67.18	67.83	66.98	68.66
R	Squamous cell carcinoma and variants of the Cervix Uteri	1 yr	24,150	87.16	86.71	87.60	87.45	86.74	88.12
R	Squamous cell carcinoma and variants of the Cervix Uteri	5 yr	24,150	67.31	66.65	67.97	68.06	67.06	69.04
R	Adenocarcinoma and variants of the Cervix Uteri	1 yr	5,638	86.19	85.21	87.10	86.65	85.14	88.01
R	Adenocarcinoma and variants of the Cervix Uteri	5 yr	5,638	66.72	65.33	68.07	67.57	65.46	69.58
R	Undifferentiated carcinoma of the Cervix Uteri	1 yr	131	58.49	49.28	66.61	55.51	42.55	66.67
R	Undifferentiated carcinoma of the Cervix Uteri	5 yr	131	34.14	25.31	43.13	36.92	24.01	49.86
R	MIXED EPITHELIAL AND MESENCHYMAL TUMOURS OF THE UTERUS	1 yr	2,272	64.48	62.38	66.49	65.87	63.02	68.55
R	MIXED EPITHELIAL AND MESENCHYMAL TUMOURS OF THE UTERUS	5 yr	2,272	37.43	35.14	39.72	38.78	35.56	41.98
	EPITHELIAL TUMOURS OF THE OVARY AND FALLOPIAN TUBE	1 yr	49,780	68.14	67.71	68.56	69.26	68.61	69.90
	EPITHELIAL TUMOURS OF THE OVARY AND FALLOPIAN TUBE	5 yr	49,780	37.71	37.24	38.19	38.89	38.18	39.60
R	Adenocarcinoma and variants of the Ovary	1 yr	32,579	73.43	72.93	73.92	75.14	74.39	75.87
R	Adenocarcinoma and variants of the Ovary	5 yr	32,579	36.98	36.40	37.56	38.85	37.99	39.71
R	Mucinous adenocarcinoma of the Ovary	1 yr	4,861	75.16	73.87	76.39	75.50	73.35	77.51
R	Mucinous adenocarcinoma of the Ovary	5 yr	4,861	57.97	56.38	59.52	57.25	54.75	59.67
R	Clear cell adenocarcinoma of the Ovary	1 yr	1,691	79.39	77.31	81.29	81.14	78.23	83.69
R	Clear cell adenocarcinoma of the Ovary	5 yr	1,691	53.91	51.27	56.46	55.12	51.41	58.67
R	Adenocarcinoma and variants of the Fallopian tube	1 yr	1,424	79.35	77.04	81.45	83.07	79.87	85.80

R	Adenocarcinoma and variants of the Fallopian tube	5 yr	1,424	47.81	44.85	50.71	48.02	43.90	52.02
	NON EPITHELIAL TUMOURS OF THE OVARY	1 yr	2,385	75.83	74.01	77.55	78.17	75.41	80.66
	NON EPITHELIAL TUMOURS OF THE OVARY	5 yr	2,385	62.47	60.27	64.59	61.11	57.84	64.20
R	Mixed epithelial mesenchymal tumours of the Ovary	1 yr	808	46.23	42.68	49.70	55.81	50.77	60.54
R	Mixed epithelial mesenchymal tumours of the Ovary	5 yr	808	18.17	15.35	21.18	18.57	14.65	22.88
R	Sex cord tumours of the Ovary	1 yr	759	91.32	88.87	93.25	94.16	90.24	96.54
R	Sex cord tumours of the Ovary	5 yr	759	82.66	79.02	85.73	84.18	78.65	88.39
R	Malignant Immature Teratomas of the Ovary	1 yr	392	89.04	85.40	91.82	90.52	84.19	94.40
R	Malignant Immature Teratomas of the Ovary	5 yr	392	83.21	78.65	86.87	83.41	75.75	88.82
R	Germ cell tumours of the Ovary	1 yr	426	91.46	88.34	93.78	94.66	89.90	97.21
R	Germ cell tumours of the Ovary	5 yr	426	84.49	80.55	87.70	90.08	84.43	93.76
	EPITHELIAL TUMOURS OF THE VULVA & VAGINA	1 yr	10,293	78.89	78.00	79.75	79.71	78.37	80.99
	EPITHELIAL TUMOURS OF THE VULVA & VAGINA	5 yr	10,293	60.91	59.63	62.16	61.60	59.72	63.41
R	Squamous cell carcinoma and variants of the Vulva and Vagina	1 yr	8,162	79.59	78.60	80.54	80.41	78.94	81.80
R	Squamous cell carcinoma and variants of the Vulva and Vagina	5 yr	8,162	59.62	58.19	61.01	60.02	57.95	62.03
R	Adenocarcinoma and variants of the Vulva and Vagina	1 yr	431	70.72	65.87	75.00	80.22	73.27	85.54
R	Adenocarcinoma and variants of the Vulva and Vagina	5 yr	431	42.91	37.31	48.39	55.59	46.63	63.65
R	Paget disease of the Vulva and Vagina	1 yr	282	97.99	91.65	99.53	99.30	12.80	100.00
R	Paget disease of the Vulva and Vagina	5 yr	282	98.02	63.10	99.91	93.51	74.55	98.48
R	Undifferentiated carcinoma of the Vulva and Vagina	1 yr	45	48.18	32.63	62.13	46.13	22.13	67.25
R	Undifferentiated carcinoma of the Vulva and Vagina	5 yr	45	31.49	16.97	47.10	33.48	12.97	55.65
	TROPHOBLASTIC TUMOURS OF THE PLACENTA	1 yr	135	94.13	88.50	97.05	91.80	79.47	96.86
	TROPHOBLASTIC TUMOURS OF THE PLACENTA	5 yr	135	90.00	83.34	94.09	87.20	74.47	93.84
R	Choriocarcinoma of the Placenta	1 yr	135	94.13	88.50	97.05	91.80	79.47	96.86
R	Choriocarcinoma of the Placenta	5 yr	135	90.00	83.34	94.09	87.20	74.47	93.84
	EPITHELIAL TUMOURS OF THE PROSTATE	1 yr	235,753	91.14	90.99	91.29	94.36	94.19	94.53
	EPITHELIAL TUMOURS OF THE PROSTATE	5 yr	235,753	74.44	74.15	74.72	79.70	79.32	80.08
F	Adenocarcinoma and variants of the Prostate	1 yr	199,562	95.08	94.94	95.22	96.88	96.72	97.04
F	Adenocarcinoma and variants of the Prostate	5 yr	199,562	78.90	78.60	79.19	82.92	82.53	83.31
R	Squamous cell carcinoma and variants of the Prostate	1 yr	583	74.68	70.51	78.35	87.29	82.26	90.96
R	Squamous cell carcinoma and variants of the Prostate	5 yr	583	45.09	39.77	50.25	56.70	48.40	64.16
R	Infiltrating duct carcinoma of the Prostate	1 yr	2,033	95.46	93.94	96.61	98.31	96.71	99.13
R	Infiltrating duct carcinoma of the Prostate	5 yr	2,033	77.08	74.00	79.85	85.35	81.57	88.42
R	Transitional cell carcinoma of the Prostate	1 yr	369	72.19	66.67	76.97	78.85	69.54	85.61
R	Transitional cell carcinoma of the Prostate	5 yr	369	48.47	41.17	55.38	59.46	45.49	70.95
R	Salivary gland type tumours of the Prostate	1 yr	11	77.27	35.02	93.86	54.89	0.24	94.22
R	Salivary gland type tumours of the Prostate	5 yr	11	49.98	11.75	79.88	49.24	0.11	92.86
	TUMOURS OF THE TESTIS AND PARATESTIS	1 yr	16,594	97.35	97.07	97.60	97.92	97.55	98.23

	TUMOURS OF THE TESTIS AND PARATESTIS	5 yr	16,594	94.87	94.46	95.26	95.98	95.42	96.47
R	Adenocarcinoma and variants of the Paratestis	1 yr	6	69.19	18.06	92.38	76.59	10.81	96.85
R	Adenocarcinoma and variants of the Paratestis	5 yr	6	81.38	4.03	98.69	88.96	0.00	99.91
R	Malignant Immature Teratomas of the Testis	1 yr	4,421	96.94	96.37	97.42	97.72	96.95	98.29
R	Malignant Immature Teratomas of the Testis	5 yr	4,421	93.76	92.94	94.49	94.97	93.84	95.91
R	Germ cell tumours Seminomatous of the Testis	1 yr	9,090	98.92	98.64	99.14	99.23	98.85	99.48
R	Germ cell tumours Seminomatous of the Testis	5 yr	9,090	97.45	96.96	97.86	98.40	97.73	98.87
R	Germ cell tumours non Seminomatous of the Testis	1 yr	1,942	96.78	95.87	97.50	96.79	95.37	97.78
R	Germ cell tumours non Seminomatous of the Testis	5 yr	1,942	93.57	92.28	94.66	93.22	91.27	94.74
R	Trophoblastic tumours of the Testis	1 yr	102	83.46	74.66	89.42	85.67	68.69	93.83
R	Trophoblastic tumours of the Testis	5 yr	102	68.20	58.07	76.38	68.15	51.16	80.30
R	Sex Cord tumours of the Testis	1 yr	98	95.35	87.14	98.36	95.65	85.95	98.70
R	Sex Cord tumours of the Testis	5 yr	98	83.88	71.76	91.11	83.37	66.06	92.33
	EPITHELIAL TUMOURS OF THE PENIS	1 yr	3,315	86.27	84.85	87.57	85.55	83.36	87.48
	EPITHELIAL TUMOURS OF THE PENIS	5 yr	3,315	71.93	69.71	74.02	68.96	65.67	72.00
R	Squamous cell carcinoma and variants of the Penis	1 yr	3,071	87.63	86.19	88.93	86.79	84.57	88.71
R	Squamous cell carcinoma and variants of the Penis	5 yr	3,071	73.07	70.78	75.21	70.39	67.00	73.51
R	Adenocarcinoma and variants of the Penis	1 yr	27	79.40	54.50	91.60	77.97	37.31	93.92
R	Adenocarcinoma and variants of the Penis	5 yr	27	51.86	23.60	74.18	44.26	13.49	71.77
	EPITHELIAL TUMOURS OF THE KIDNEY	1 yr	53,678	71.59	71.18	71.99	73.12	72.53	73.69
	EPITHELIAL TUMOURS OF THE KIDNEY	5 yr	53,678	56.80	56.28	57.30	58.21	57.48	58.94
F	Renal cell carcinoma and variants	1 yr	43,488	79.47	79.06	79.87	80.53	79.95	81.10
F	Renal cell carcinoma and variants	5 yr	43,488	63.77	63.22	64.32	64.96	64.18	65.73
R	Squamous cell carcinoma spindle cell type of the Kidney	1 yr	31	20.07	8.11	35.82	24.42	8.84	44.07
R	Squamous cell carcinoma spindle cell type of the Kidney	5 yr	31	7.88	1.35	22.33	22.45	6.40	44.39
R	Squamous cell carcinoma and variants of the Kidney	1 yr	186	26.72	20.44	33.38	34.34	23.98	44.93
R	Squamous cell carcinoma and variants of the Kidney	5 yr	186	12.39	7.72	18.21	15.11	7.49	25.21
	EPITHELIAL TUMOURS OF THE PELVIS, URETER AND URETHRA	1 yr	8,308	75.23	74.21	76.21	74.57	73.10	75.97
	EPITHELIAL TUMOURS OF THE PELVIS, URETER AND URETHRA	5 yr	8,308	53.49	52.14	54.83	51.56	49.69	53.40
R	Transitional cell carcinoma of the Pelvis, Ureter Urethra	1 yr	7,216	77.79	76.73	78.81	76.68	75.15	78.13
R	Transitional cell carcinoma of the Pelvis, Ureter Urethra	5 yr	7,216	55.98	54.52	57.40	53.57	51.57	55.52
R	Squamous cell carcinoma and variants of the Pelvis, Ureter Urethra	1 yr	290	54.54	48.36	60.30	57.63	47.32	66.63
R	Squamous cell carcinoma and variants of the Pelvis, Ureter Urethra	5 yr	290	32.89	26.59	39.31	38.98	28.29	49.52
R	Adenocarcinoma and variants of the Pelvis, Ureter Urethra	1 yr	182	77.28	69.92	83.05	78.93	69.44	85.77
R	Adenocarcinoma and variants of the Pelvis, Ureter Urethra	5 yr	182	47.91	38.94	56.33	43.25	31.32	54.60
R	Salivary gland type tumours of the Pelvis, Ureter Urethra	1 yr	1	108.81	—	—	101.84	—	—
R	Salivary gland type tumours of the Pelvis, Ureter Urethra	5 yr	1	0.00	—	—	NE	NE	NE
	EPITHELIAL TUMOURS OF THE BLADDER	1 yr	112,695	81.26	81.00	81.51	79.48	79.06	79.90

	EPITHELIAL TUMOURS OF THE BLADDER	5 yr	112,695	65.59	65.20	65.97	62.98	62.40	63.56
F	Transitional cell carcinoma of the Bladder	1 yr	98,665	84.72	84.46	84.98	82.88	82.45	83.29
F	Transitional cell carcinoma of the Bladder	5 yr	98,665	68.47	68.06	68.88	65.68	65.06	66.28
R	Squamous cell carcinoma and variants of the Bladder	1 yr	2,373	48.03	45.90	50.13	42.29	38.97	45.56
R	Squamous cell carcinoma and variants of the Bladder	5 yr	2,373	33.50	31.17	35.85	27.01	23.77	30.34
R	Adenocarcinoma and variants of the Bladder	1 yr	1,583	67.47	64.94	69.86	67.58	63.65	71.19
R	Adenocarcinoma and variants of the Bladder	5 yr	1,583	40.30	37.36	43.22	42.03	37.64	46.35
R	Salivary gland type tumours of the Bladder	1 yr	8	79.02	27.59	95.79	106.59	—	—
R	Salivary gland type tumours of the Bladder	5 yr	8	66.26	10.90	92.64	NE	NE	NE
	EPITHELIAL TUMOURS OF THE EYE AND ADNEXA	1 yr	835	90.37	87.70	92.49	91.09	86.88	94.00
	EPITHELIAL TUMOURS OF THE EYE AND ADNEXA	5 yr	835	79.96	75.61	83.62	80.74	74.01	85.89
R	Squamous cell carcinoma and variants of the Eye Adnexa	1 yr	217	94.31	87.98	97.35	94.64	79.80	98.67
R	Squamous cell carcinoma and variants of the Eye Adnexa	5 yr	217	80.72	70.28	87.80	86.03	64.40	94.98
R	Adenocarcinoma and variants of the Eye Adnexa	1 yr	60	87.54	74.40	94.19	95.51	63.80	99.53
R	Adenocarcinoma and variants of the Eye Adnexa	5 yr	60	63.60	46.63	76.45	66.74	36.66	84.96
	EPITHELIAL TUMOURS OF THE MIDDLE EAR	1 yr	170	60.83	52.69	68.01	71.04	57.27	81.09
	EPITHELIAL TUMOURS OF THE MIDDLE EAR	5 yr	170	42.37	33.56	50.90	43.01	29.98	55.37
R	Squamous cell carcinoma and variants of the Middle Ear	1 yr	126	55.26	45.75	63.76	69.20	53.31	80.62
R	Squamous cell carcinoma and variants of the Middle Ear	5 yr	126	32.22	23.03	41.74	33.53	20.30	47.29
R	Adenocarcinoma and variants of the Middle Ear	1 yr	20	97.12	36.85	99.91	90.00	38.91	98.83
R	Adenocarcinoma and variants of the Middle Ear	5 yr	20	90.19	38.04	98.90	91.50	9.29	99.67
	MALIGNANT MESOTHELIOMA	1 yr	9,707	34.77	33.80	35.75	36.75	35.36	38.14
	MALIGNANT MESOTHELIOMA	5 yr	9,707	5.49	5.00	6.02	5.36	4.69	6.09
R	Mesothelioma of the pleura and pericardium	1 yr	8,201	36.05	34.98	37.12	37.50	36.00	39.01
R	Mesothelioma of the pleura and pericardium	5 yr	8,201	4.89	4.39	5.44	4.64	3.98	5.37
R	Mesothelioma of the peritoneum tunica vaginalis	1 yr	634	30.66	27.04	34.35	29.32	24.42	34.39
R	Mesothelioma of the peritoneum tunica vaginalis	5 yr	634	11.30	8.76	14.21	10.21	7.15	13.90
F	MALIGNANT SKIN MELANOMA	1 yr	64,137	95.45	95.24	95.64	95.97	95.69	96.23
F	MALIGNANT SKIN MELANOMA	5 yr	64,137	84.37	83.98	84.76	85.08	84.53	85.61
R	MALIGNANT MELANOMA OF THE MUCOSA	1 yr	2,621	59.93	57.94	61.87	59.18	56.39	61.85
R	MALIGNANT MELANOMA OF THE MUCOSA	5 yr	2,621	29.52	27.52	31.55	29.40	26.69	32.15
R	MALIGNANT MELANOMA OF THE UVEA	1 yr	3,696	95.09	94.13	95.89	94.82	93.14	96.10
R	MALIGNANT MELANOMA OF THE UVEA	5 yr	3,696	72.52	70.62	74.31	69.22	66.34	71.91
	EPITHELIAL TUMOURS OF THE SKIN	1 yr	235,530	99.82	99.69	99.89	100.05	—	—
	EPITHELIAL TUMOURS OF THE SKIN	5 yr	235,530	97.71	97.46	97.94	97.60	97.24	97.91
F	Basal cell carcinoma of the Skin	1 yr	154,567	100.72	—	—	101.00	—	—
F	Basal cell carcinoma of the Skin	5 yr	154,567	100.68	—	—	100.87	—	—
F	Squamous cell carcinoma and variants of the Skin	1 yr	80,185	98.13	97.91	98.33	98.38	98.07	98.64

F	Squamous cell carcinoma and variants of the Skin	5 yr	80,185	91.56	91.06	92.04	91.10	90.40	91.74
R	ADNEXAL CARCINOMA OF THE SKIN	1 yr	1,441	95.40	93.43	96.79	95.90	92.73	97.70
R	ADNEXAL CARCINOMA OF THE SKIN	5 yr	1,441	86.64	82.80	89.68	87.12	81.59	91.08
	EMBRYONAL NEOPLASMS	1 yr	1,925	90.17	88.74	91.44	92.93	90.79	94.58
	EMBRYONAL NEOPLASMS	5 yr	1,925	76.76	74.76	78.61	81.69	78.72	84.29
R	Neuroblastoma and ganglioneuroblastoma	1 yr	674	85.30	82.37	87.78	87.84	83.14	91.29
R	Neuroblastoma and ganglioneuroblastoma	5 yr	674	60.04	56.15	63.70	67.59	61.54	72.90
R	Nephroblastoma	1 yr	775	93.77	91.79	95.28	96.40	93.65	97.97
R	Nephroblastoma	5 yr	775	85.96	83.25	88.27	89.40	85.47	92.32
R	Retinoblastoma	1 yr	316	99.27	96.85	99.83	100.16	—	—
R	Retinoblastoma	5 yr	316	97.11	94.36	98.53	99.16	90.10	99.93
R	Hepatoblastoma	1 yr	133	74.73	66.36	81.30	83.81	68.61	92.05
R	Hepatoblastoma	5 yr	133	62.43	53.42	70.19	70.64	54.98	81.71
R	Pulmonary blastoma	1 yr	22	73.17	49.23	87.13	72.69	26.52	92.62
R	Pulmonary blastoma	5 yr	22	44.77	22.12	65.17	55.58	19.26	81.10
R	Pancreatoblastoma	1 yr	5	100.08	—	—	100.09	—	—
R	Pancreatoblastoma	5 yr	5	100.23	—	—	100.20	—	—
	EXTRAGONADIC GERM CELL TUMOURS	1 yr	672	82.45	79.31	85.15	83.20	78.57	86.91
	EXTRAGONADIC GERM CELL TUMOURS	5 yr	672	69.17	65.39	72.63	70.60	65.05	75.44
R	Extragenadic malignant Immature Teratomas	1 yr	219	81.22	75.28	85.86	81.94	72.93	88.18
R	Extragenadic malignant Immature Teratomas	5 yr	219	65.25	58.27	71.35	62.42	51.87	71.30
R	Extragenadic Germ cell tumours	1 yr	453	83.04	79.21	86.23	83.80	78.11	88.12
R	Extragenadic Germ cell tumours	5 yr	453	71.05	66.47	75.13	74.25	67.57	79.76
	SOFT TISSUE SARCOMA	1 yr	25,691	76.26	75.71	76.80	77.06	76.24	77.86
	SOFT TISSUE SARCOMA	5 yr	25,691	55.82	55.11	56.52	57.92	56.88	58.94
R	Soft tissue sarcoma of the Head and Neck	1 yr	1,609	82.31	80.11	84.30	81.55	78.06	84.54
R	Soft tissue sarcoma of the Head and Neck	5 yr	1,609	64.56	61.37	67.56	64.84	60.11	69.17
R	Soft tissue sarcoma of the Limbs	1 yr	5,581	87.00	85.99	87.95	86.40	84.85	87.81
R	Soft tissue sarcoma of the Limbs	5 yr	5,581	67.15	65.59	68.65	68.11	65.84	70.27
R	Soft tissue sarcoma of the Superficial Trunk	1 yr	2,556	69.25	67.34	71.08	66.37	63.40	69.16
R	Soft tissue sarcoma of the Superficial Trunk	5 yr	2,556	47.48	45.22	49.70	44.19	40.99	47.35
R	Soft tissue sarcoma of the Mediastinum	1 yr	148	50.93	42.46	58.78	47.08	34.36	58.79
R	Soft tissue sarcoma of the Mediastinum	5 yr	148	22.67	15.85	30.24	14.57	7.59	23.72
R	Soft tissue sarcoma of the Heart	1 yr	85	40.28	29.80	50.52	43.32	24.79	60.55
R	Soft tissue sarcoma of the Heart	5 yr	85	12.96	6.65	21.43	10.00	2.87	22.46
R	Soft tissue sarcoma of the Breast	1 yr	1,035	91.80	89.74	93.46	93.94	90.89	95.99
R	Soft tissue sarcoma of the Breast	5 yr	1,035	78.40	75.17	81.26	81.34	76.75	85.12
R	Soft tissue sarcoma of the Uterus	1 yr	2,660	74.01	72.25	75.67	74.78	72.20	77.16

R	Soft tissue sarcoma of the Uterus	5 yr	2,660	50.45	48.36	52.49	49.37	46.36	52.30
R	Soft tissue sarcoma of the Genitourinary other	1 yr	1,307	67.41	64.68	69.98	72.20	68.07	75.90
R	Soft tissue sarcoma of the Genitourinary other	5 yr	1,307	47.43	44.28	50.51	54.11	49.23	58.72
R	Soft tissue sarcoma of the other Viscera	1 yr	2,808	65.69	63.82	67.48	65.66	62.76	68.39
R	Soft tissue sarcoma of the other Viscera	5 yr	2,808	39.78	37.69	41.86	45.47	42.21	48.67
R	Soft tissue sarcoma of the Paratesticular region	1 yr	187	94.89	88.60	97.75	97.25	82.65	99.59
R	Soft tissue sarcoma of the Paratesticular region	5 yr	187	87.53	76.89	93.47	90.56	70.90	97.18
R	Soft tissue sarcoma of the Retroperitoneum and Peritoneum	1 yr	1,585	64.27	61.77	66.66	67.45	63.72	70.90
R	Soft tissue sarcoma of the Retroperitoneum and Peritoneum	5 yr	1,585	37.25	34.57	39.93	42.77	38.67	46.80
R	Soft tissue sarcoma of the Pelvis	1 yr	82	62.60	50.77	72.35	65.80	45.34	80.13
R	Soft tissue sarcoma of the Pelvis	5 yr	82	34.60	23.38	46.07	42.39	23.39	60.22
R	Soft tissue sarcoma of the Skin	1 yr	1,562	97.03	95.64	97.98	97.63	95.51	98.76
R	Soft tissue sarcoma of the Skin	5 yr	1,562	92.39	89.89	94.30	94.39	90.67	96.66
R	Soft tissue sarcoma of the Paraorbital region	1 yr	35	81.20	63.04	91.03	83.97	54.03	95.16
R	Soft tissue sarcoma of the Paraorbital region	5 yr	35	64.77	44.50	79.22	79.40	44.20	93.69
R	Soft tissue sarcoma of the Brain and other Nervous System	1 yr	1,055	78.68	75.97	81.12	75.59	71.39	79.27
R	Soft tissue sarcoma of the Brain and other Nervous System	5 yr	1,055	55.21	51.80	58.47	52.84	48.05	57.39
R	Embryonal rhabdomyosarcoma of the Soft Tissue	1 yr	333	87.91	83.86	91.00	87.15	80.33	91.72
R	Embryonal rhabdomyosarcoma of the Soft Tissue	5 yr	333	67.31	61.87	72.15	62.58	53.95	70.05
R	Alveolar rhabdomyosarcoma of the Soft Tissue	1 yr	178	77.97	71.04	83.44	72.36	60.73	81.07
R	Alveolar rhabdomyosarcoma of the Soft Tissue	5 yr	178	41.25	33.67	48.65	36.72	25.92	47.56
R	Ewing's family tum of the Soft Tissue	1 yr	110	82.87	74.38	88.76	81.26	70.24	88.53
R	Ewing's family tum of the Soft Tissue	5 yr	110	52.14	42.30	61.09	50.99	38.40	62.24
	BONE SARCOMA	1 yr	4,443	83.40	82.23	84.51	83.88	82.04	85.55
	BONE SARCOMA	5 yr	4,443	60.47	58.87	62.03	61.45	59.04	63.76
R	Osteogenic sarcomas	1 yr	1,258	81.94	79.65	84.01	81.77	78.06	84.91
R	Osteogenic sarcomas	5 yr	1,258	54.40	51.44	57.26	54.01	49.53	58.27
R	Chondrogenic sarcomas	1 yr	1,325	87.84	85.81	89.60	88.32	85.19	90.82
R	Chondrogenic sarcomas	5 yr	1,325	73.80	70.85	76.50	76.18	71.80	79.97
R	Notochordal sarcoma, Chordoma	1 yr	231	83.95	78.13	88.34	88.15	79.50	93.31
R	Notochordal sarcoma, Chordoma	5 yr	231	64.99	57.12	71.79	77.31	65.22	85.65
R	Vascular sarcoma, Angiosarcoma	1 yr	20	35.75	15.91	56.24	40.92	5.13	76.43
R	Vascular sarcoma, Angiosarcoma	5 yr	20	27.96	9.91	49.54	34.72	4.22	70.22
R	Ewing's family of tum	1 yr	737	82.31	79.35	84.89	84.91	79.66	88.89
R	Ewing's family of tum	5 yr	737	49.72	45.99	53.32	52.22	46.08	58.00
R	Epithelial tumours, Adamantinoma	1 yr	48	91.58	76.60	97.14	96.40	64.32	99.70
R	Epithelial tumours, Adamantinoma	5 yr	48	83.93	62.72	93.63	83.59	43.54	96.21
R	Other high grade sarcoma (fibrosarcoma, malignant fibrous histiocytoma)	1 yr	106	77.27	67.52	84.43	75.89	57.17	87.27

R	Other high grade sarcoma (fibrosarcoma, malignant fibrous histiocytoma)	5 yr	106	52.46	41.17	62.56	53.91	36.12	68.74
R	GASTROINTESTINAL STROMAL SARCOMA	1 yr	181	84.02	77.22	88.93	83.54	78.88	87.26
R	GASTROINTESTINAL STROMAL SARCOMA	5 yr	181	70.53	61.18	78.02	67.95	59.41	75.08
R	KAPOSI SARCOMA	1 yr	2,122	78.10	76.14	79.91	86.51	83.37	89.09
R	KAPOSI SARCOMA	5 yr	2,122	64.03	61.48	66.47	74.99	70.68	78.76
	NEURO ENDOCRINE TUMOURS	1 yr	12,636	67.44	66.57	68.28	67.14	65.97	68.28
	NEURO ENDOCRINE TUMOURS	5 yr	12,636	50.75	49.72	51.78	49.57	48.18	50.95
R	Well differentiated endocrine tumours, carcinoid	1 yr	1,712	61.74	59.30	64.07	56.40	53.31	59.36
R	Well differentiated endocrine tumours, carcinoid	5 yr	1,712	32.21	29.71	34.73	29.43	26.43	32.48
R	Well differentiated endocrine tumours, atypical carcinoid	1 yr	1	100.32	—	—	58.47	9.46	88.51
R	Well differentiated endocrine tumours, atypical carcinoid	5 yr	1	101.82	—	—	NE	NE	NE
R	Poorly differentiated endocrine carcinoma (lung microcytoma excluded)	1 yr	2,680	30.09	28.32	31.89	30.40	27.92	32.90
R	Poorly differentiated endocrine carcinoma (lung microcytoma excluded)	5 yr	2,680	12.88	11.47	14.37	11.73	9.94	13.68
R	Mixed endocrine-exocrine carcinoma	1 yr	10	30.79	7.20	59.02	84.01	25.70	97.79
R	Mixed endocrine-exocrine carcinoma	5 yr	10	34.81	7.52	65.03	62.15	14.32	89.01
R	Endocrine carcinoma of the Thyroid gland	1 yr	1,135	90.50	88.50	92.17	92.96	90.30	94.91
R	Endocrine carcinoma of the Thyroid gland	5 yr	1,135	80.47	77.53	83.07	82.29	78.00	85.82
R	Well differentiated endocrine carcinoma not functioning of the Pancreas and of the Digestive organs	1 yr	6,300	78.99	77.90	80.04	78.70	77.19	80.12
R	Well differentiated endocrine carcinoma not functioning of the Pancreas and of the Digestive organs	5 yr	6,300	64.44	62.98	65.85	64.02	62.03	65.94
R	Well differentiated endocrine carcinoma functioning of the Pancreas and of the Digestive organs	1 yr	143	77.62	69.51	83.82	80.60	65.87	89.46
R	Well differentiated endocrine carcinoma functioning of the Pancreas and of the Digestive organs	5 yr	143	51.26	41.68	60.04	53.17	38.05	66.16
R	Endocrine carcinoma of the Skin	1 yr	621	80.19	76.16	83.61	85.47	80.50	89.25
R	Endocrine carcinoma of the Skin	5 yr	621	57.58	51.56	63.13	57.83	49.81	65.03
	CARCINOMA OF ENDOCRINE ORGANS	1 yr	21,082	87.81	87.34	88.27	90.31	89.70	90.88
	CARCINOMA OF ENDOCRINE ORGANS	5 yr	21,082	84.52	83.89	85.12	87.14	86.30	87.93
R	Carcinomas of the Pituitary gland	1 yr	212	76.54	69.76	82.00	82.23	70.01	89.82
R	Carcinomas of the Pituitary gland	5 yr	212	67.86	59.22	75.06	66.72	51.69	78.03
R	Carcinomas of the Thyroid gland	1 yr	18,797	90.42	89.96	90.86	92.68	92.11	93.21
R	Carcinomas of the Thyroid gland	5 yr	18,797	88.15	87.53	88.73	90.55	89.73	91.31
R	Carcinomas of the Parathyroid gland	1 yr	112	87.56	79.08	92.76	90.01	77.71	95.70
R	Carcinomas of the Parathyroid gland	5 yr	112	72.75	61.12	81.42	83.37	63.83	92.90
R	Carcinoma of the Adrenal gland	1 yr	940	62.53	59.28	65.61	60.14	55.18	64.73
R	Carcinoma of the Adrenal gland	5 yr	940	39.45	36.06	42.82	36.47	31.70	41.25
	GLIAL TUMOURS OF THE CENTRAL NERVOUS SYSTEM (CNS) AND PINEAL GLAND	1 yr	28,838	42.03	41.46	42.61	43.78	42.90	44.66

	GLIAL TUMOURS OF THE CENTRAL NERVOUS SYTEM (CNS) AND PINEAL GLAND	5 yr	28,838	20.01	19.52	20.50	19.57	18.86	20.29
R	Astrocytic tumours of the CNS	1 yr	25,827	37.23	36.63	37.83	38.95	38.04	39.87
R	Astrocytic tumours of the CNS	5 yr	25,827	15.07	14.60	15.54	14.43	13.77	15.11
R	Oligodendroglial tumours of the CNS	1 yr	1,941	81.11	79.26	82.81	82.41	79.59	84.87
R	Oligodendroglial tumours of the CNS	5 yr	1,941	54.03	51.65	56.35	54.47	50.97	57.84
R	Ependymal tumours of the CNS	1 yr	1,070	86.05	83.77	88.03	90.13	86.95	92.58
R	Ependymal tumours of the CNS	5 yr	1,070	71.26	68.24	74.06	74.48	70.05	78.36
	NON GLIAL TUMOURS OF THE CENTRAL NERVOUS SYSTEM (CNS) AND PINEAL GLAND	1 yr	1,202	78.25	75.80	80.49	81.02	77.46	84.07
	NON GLIAL TUMOUR OF THE CENTRAL NERVOUS SYSTEM (CNS) AND PINEAL GLAND	5 yr	1,202	53.11	50.19	55.94	56.93	52.57	61.05
R	Embryonal tumours of the CNS	1 yr	1,178	78.31	75.84	80.57	81.14	77.50	84.24
R	Embryonal tumours of the CNS	5 yr	1,178	53.23	50.28	56.09	56.80	52.37	60.99
R	Choroid plexus carcinoma of the CNS	1 yr	24	75.42	52.74	88.30	78.39	55.25	90.49
R	Choroid plexus carcinoma of the CNS	5 yr	24	46.85	25.78	65.43	64.56	39.09	81.56
R	MALIGNANT MENINGIOMAS	1 yr	865	77.05	73.94	79.84	80.09	74.92	84.31
R	MALIGNANT MENINGIOMAS	5 yr	865	61.75	57.75	65.50	69.95	63.70	75.33
	GLIAL TUMOURS OF THE OF THE NERVES, AUTONOMIC NERVOUS SYSTEM AND PARAGANGLIA	1 yr	55	91.43	79.47	96.57	75.50	52.76	88.37
	GLIAL TUMOURS OF THE OF THE NERVES, AUTONOMIC NERVOUS SYSTEM AND PARAGANGLIA	5 yr	55	86.48	71.97	93.78	72.00	48.62	86.10
R	Astrocytic tumours of the Nerves, Autonomic Nervous System and Paraganglia	1 yr	27	81.95	61.19	92.25	50.59	20.95	74.31
R	Astrocytic tumours of the Nerves, Autonomic Nervous System and Paraganglia	5 yr	27	68.65	46.56	83.10	41.85	16.09	66.01
R	Ependymal tumours of the Nerves, Autonomic Nervous System and Paraganglia	1 yr	28	100.76	—	—	100.14	—	—
R	Ependymal tumours of the Nerves, Autonomic Nervous System and Paraganglia	5 yr	28	104.36	—	—	103.78	—	—
	NON-GLIAL TUMOURS OF THE OF THE NERVES, AUTONOMIC NERVOUS SYSTEM AND PARAGANGLIA	1 yr	514	85.60	82.11	88.46	83.74	78.36	87.89
	NON-GLIAL TUMOURS OF THE OF THE NERVES, AUTONOMIC NERVOUS SYSTEM AND PARAGANGLIA	5 yr	514	63.50	58.75	67.85	59.63	52.83	65.77
R	Embryonal tumours of the Nerves, Autonomic Nervous System and Paraganglia	1 yr	401	87.43	83.60	90.41	85.40	79.03	89.95
R	Embryonal tumours of the Nerves, Autonomic Nervous System and Paraganglia	5 yr	401	67.01	61.71	71.74	64.87	56.95	71.69
R	Paraganglioma	1 yr	113	79.09	70.00	85.70	79.62	68.01	87.39
R	Paraganglioma	5 yr	113	51.00	40.47	60.58	42.84	29.65	55.37
	LYMPHOID DISEASES	1 yr	156,200	75.70	75.47	75.92	76.83	76.49	77.17

	LYMPHOID DISEASES	5 yr	156,200	55.21	54.91	55.51	56.05	55.60	56.49
R	Classical Hodgkin Lymphoma	1 yr	13,055	91.14	90.61	91.64	91.77	90.97	92.50
R	Classical Hodgkin Lymphoma	5 yr	13,055	82.18	81.41	82.93	83.63	82.48	84.70
R	Hodgkin lymphoma nodular lymphocyte predominance	1 yr	256	96.55	93.14	98.28	98.14	93.55	99.47
R	Hodgkin lymphoma nodular lymphocyte predominance	5 yr	256	92.48	87.55	95.50	94.38	87.39	97.55
R	Composite Hodgkin/NHL	1 yr	30	85.95	64.68	94.87	79.89	34.52	95.37
R	Composite Hodgkin/NHL	5 yr	30	59.63	35.18	77.42	50.17	16.74	76.63
R	Precursor B/T lymphoblastic leukaemia/lymphoblastic lymphoma	1 yr	7,015	75.52	74.47	76.53	76.20	74.57	77.73
R	Precursor B/T lymphoblastic leukaemia/lymphoblastic lymphoma	5 yr	7,015	58.51	57.27	59.72	58.63	56.74	60.46
R	Non Hodgkin Mature T cell and NK cell neoplasms	1 yr	5,076	77.65	76.40	78.84	73.74	71.89	75.49
R	Non Hodgkin Mature T cell and NK cell neoplasms	5 yr	5,076	63.66	62.01	65.25	59.34	57.08	61.52
F	Non Hodgkin Mature B cell lymphoma	1 yr	92,372	77.36	77.06	77.65	77.87	77.44	78.29
F	Non Hodgkin Mature B cell lymphoma	5 yr	92,372	52.48	52.08	52.88	52.98	52.40	53.55
	ACUTE MYELOID LEUKAEMIA AND RELATED PRECURSOR NEOPLASMS	1 yr	18,989	38.02	37.31	38.73	36.73	35.69	37.77
	ACUTE MYELOID LEUKAEMIA AND RELATED PRECURSOR NEOPLASMS	5 yr	18,989	19.80	19.16	20.45	18.85	17.95	19.77
R	Acute Myeloid Leukemia with recurrent genetic abnormalities	1 yr	601	68.38	64.39	72.01	67.08	61.33	72.17
R	Acute Myeloid Leukemia with recurrent genetic abnormalities	5 yr	601	60.98	56.52	65.13	62.66	56.23	68.42
R	Acute myeloid leukemia NOS (FAB or WHO type)	1 yr	14,614	35.20	34.40	35.99	33.40	32.24	34.57
R	Acute myeloid leukemia NOS (FAB or WHO type)	5 yr	14,614	17.57	16.88	18.27	15.80	14.86	16.77
R	AML with myelodysplasia related and RAEBT-T	1 yr	282	42.34	36.24	48.29	31.25	23.03	39.79
R	AML with myelodysplasia related and RAEBT-T	5 yr	282	8.74	5.22	13.37	3.75	1.09	9.19
R	Therapy related myeloid neoplasms	1 yr	3	0.00	—	—	33.80	4.60	68.23
R	Therapy related myeloid neoplasms	5 yr	3	0.00	—	—	NE	NE	NE
R	Acute Myeloid Leukemia NOS and other AML	1 yr	2,513	43.32	41.31	45.31	44.33	41.53	47.10
R	Acute Myeloid Leukemia NOS and other AML	5 yr	2,513	22.35	20.54	24.22	23.97	21.36	26.66
R	Myeloid sarcoma	1 yr	67	51.82	38.87	63.30	69.38	53.67	80.67
R	Myeloid sarcoma	5 yr	67	22.73	12.65	34.60	20.24	5.13	42.34
R	Blastic plasmacytoid dendritic cell neoplasm*	1 yr							
R	Blastic plasmacytoid dendritic cell neoplasm	5 yr							
	MYELOPROLIFERATIVE NEOPLASMS	1 yr	16,451	82.17	81.52	82.81	85.63	84.68	86.53
	MYELOPROLIFERATIVE NEOPLASMS	5 yr	16,451	59.71	58.75	60.66	61.61	60.13	63.05
R	Chronic myeloid leukemia	1 yr	6,848	73.61	72.47	74.70	76.42	74.62	78.11
R	Chronic myeloid leukemia	5 yr	6,848	41.71	40.32	43.09	43.96	41.83	46.06
R	Myelosclerosis with myeloid metaplasia	1 yr	688	80.27	76.75	83.31	78.71	73.04	83.32
R	Myelosclerosis with myeloid metaplasia	5 yr	688	42.53	38.01	46.98	34.91	28.24	41.66
R	Essential thrombocythemia	1 yr	2,478	95.43	94.16	96.42	97.93	96.06	98.92
R	Essential thrombocythemia	5 yr	2,478	87.53	85.08	89.61	90.31	86.47	93.10

R	Polycythemia vera	1 yr	3,678	92.40	91.30	93.37	95.51	93.83	96.74
R	Polycythemia vera	5 yr	3,678	81.22	79.28	82.99	83.98	80.69	86.76
R	Mast cell tumours	1 yr	77	78.93	67.64	86.67	90.53	75.26	96.57
R	Mast cell tumours	5 yr	77	72.17	58.99	81.74	79.16	60.58	89.68
R	Myeloproliferative diseases other	1 yr	2,679	78.41	76.61	80.09	82.71	80.26	84.88
R	Myeloproliferative diseases other	5 yr	2,679	54.70	52.16	57.17	57.21	53.47	60.78
R	MYELODISPLASTIC SYNDROME	1 yr	7,781	70.11	68.95	71.23	67.12	65.35	68.82
R	MYELODISPLASTIC SYNDROME	5 yr	7,781	37.22	35.75	38.68	29.12	27.06	31.20
	MYELODISPLASTIC MYELOPROLIFERATIVE DISEASES	1 yr	1,538	60.21	57.50	62.80	55.06	51.08	58.86
	MYELODISPLASTIC MYELOPROLIFERATIVE DISEASES	5 yr	1,538	22.66	20.05	25.38	18.36	15.03	21.96
R	Chronic myelomonocytic leukemia NOS	1 yr	1,536	60.15	57.44	62.75	54.73	50.73	58.55
R	Chronic myelomonocytic leukemia NOS	5 yr	1,536	22.53	19.92	25.24	18.07	14.76	21.65
R	Juvenile myelomonocytic leukemia	1 yr	1	100.03	—	—	100.20	—	—
R	Juvenile myelomonocytic leukemia	5 yr	1	NE	NE	NE	NE	NE	NE
R	Atypical chronic myeloid leukemia BCRABL negative	1 yr	1	101.30	—	—	81.60	17.28	97.67
R	Atypical chronic myeloid leukemia BCRABL negative	5 yr	1	NE	NE	NE	NE	NE	NE
R	HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS	1 yr	268	79.39	73.91	83.85	91.26	83.73	95.40
R	HISTIOCYTIC AND DENDRITIC CELL NEOPLASMS	5 yr	268	71.70	65.33	77.10	82.68	73.55	88.89

* ICD-O3 code not available

F frequent tumour entity; R rare tumour entity, NE not estimated